{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true,
      "authorship_tag": "ABX9TyNOIjxT0yR7wVpV6E72jqsT",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/mindcatch/datasharing/blob/master/text_splitter.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "\n",
        "# 2. 로컬 드라이브에서 문서 파일 읽기\n",
        "file_name = \"/Users/home/Downloads/B3-summary-2022 5th WHO, 2023 ICC- myeloid.pdf\"  # 파일 경로\n",
        "\n",
        "\n",
        "\n",
        "# 파일 내용 읽기\n",
        "with open(file_name, 'r') as file:\n",
        "    document_content = file.read()\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 259
        },
        "id": "PRKU7iD-e2Fu",
        "outputId": "005b250d-ba3c-440f-a64f-4d1437c9d355"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "error",
          "ename": "FileNotFoundError",
          "evalue": "[Errno 2] No such file or directory: '/Users/home/Downloads/B3-summary-2022 5th WHO, 2023 ICC- myeloid.pdf'",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-2-611fec9c9b29>\u001b[0m in \u001b[0;36m<cell line: 7>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      6\u001b[0m \u001b[0;31m# 파일 내용 읽기\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 7\u001b[0;31m \u001b[0;32mwith\u001b[0m \u001b[0mopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfile_name\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'r'\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0mfile\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      8\u001b[0m     \u001b[0mdocument_content\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfile\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: '/Users/home/Downloads/B3-summary-2022 5th WHO, 2023 ICC- myeloid.pdf'"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# 필요한 라이브러리 설치\n",
        "!pip install PyPDF2 langchain"
      ],
      "metadata": {
        "id": "GebtDGtfgfSs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import PyPDF2\n",
        "from langchain.text_splitter import TextSplitter"
      ],
      "metadata": {
        "id": "v2kuEZi1gl2k"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "YzUT2QzCdlB3"
      },
      "outputs": [],
      "source": [
        "# 1. 필요한 라이브러리 설치\n",
        "!pip install langchain\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import RecursiveCharacterTextSplitter"
      ],
      "metadata": {
        "id": "QctCU41iioxB"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# PDF 파일 경로\n",
        "file_path = '/B3-summary-2022 5th WHO, 2023 ICC- myeloid.pdf'\n",
        "\n",
        "# PDF 파일 읽기\n",
        "with open(file_path, 'rb') as file:\n",
        "    reader = PyPDF2.PdfReader(file)\n",
        "    document_content = \"\"\n",
        "    for page in reader.pages:\n",
        "        document_content += page.extract_text()"
      ],
      "metadata": {
        "id": "LlX1ScyVgwBD"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# 3. text_splitter로 텍스트 분할\n",
        "from langchain.text_splitter import TextSplitter\n",
        "\n",
        "# RecursiveCharacterTextSplitter로 텍스트 분할\n",
        "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=300)\n",
        "chunks = text_splitter.split_text(document_content)\n",
        "\n"
      ],
      "metadata": {
        "id": "5cSNgT1Ae5OH"
      },
      "execution_count": 20,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# 청크 개수, 크기 및 내용 출력\n",
        "print(f\"Total number of chunks: {len(chunks)}\")\n",
        "for i, chunk in enumerate(chunks):\n",
        "    chunk_size = len(chunk)\n",
        "    print(f\"Chunk #{i+1}, Size: {chunk_size}\")\n",
        "    print(\"Content:\", chunk)\n",
        "    print(\"------------------------------------------------------------\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "C9X_jmJ2iaaT",
        "outputId": "9b66f712-2733-4466-896e-0e492da08514"
      },
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Total number of chunks: 38\n",
            "Chunk #1, Size: 934\n",
            "Content: #MDS  #ICC  #CMML  #JMML\n",
            "Cytopenia definitions 2022, 5th WHO classification (WHO-\n",
            "HAEM5)\n",
            "Overview of 4th WHO 2016 Criteria (WHO-HAEM4) for\n",
            "Myelodysplastic Syndromes (MDS)\n",
            "Cytopenia Levels\n",
            "Definition : Cytopenias are defined as follows:\n",
            "Diagnostic Implications\n",
            "Classification of Myeloproliferative neoplasms (MPN)\n",
            "2022, 5th WHO classification (WHO-HAEM5) of MPNHarmonized for CCUS, MDS, and MDS/MPN\n",
            "Hb <13 g/dL  in males and <12 g/dL  in females for anemia -\n",
            "Absolute neutrophil count <1.8×109/L  for leukopenia\n",
            "Platelets <150×109/L  for thrombocytopenia\n",
            "Haemoglobin concentration < 10 g/dL\n",
            "Platelet count < 100 x 10^9/L\n",
            "Absolute neutrophil count (ANC) < 1.8 x 10^9/L\n",
            "Peripheral Blood Monocytes : Must be < 1 x 10^9/L.\n",
            "Study Reference : Greenberg PL, Tuechler H, Schanz J, et al. \"Cytopenia levels for\n",
            "aiding establishment of the diagnosis of myelodysplastic syndromes.\" Blood\n",
            "2016;128:2096-7.\n",
            "Impact of Cytopenia Levels in Diagnosis :\n",
            "------------------------------------------------------------\n",
            "Chunk #2, Size: 984\n",
            "Content: Peripheral Blood Monocytes : Must be < 1 x 10^9/L.\n",
            "Study Reference : Greenberg PL, Tuechler H, Schanz J, et al. \"Cytopenia levels for\n",
            "aiding establishment of the diagnosis of myelodysplastic syndromes.\" Blood\n",
            "2016;128:2096-7.\n",
            "Impact of Cytopenia Levels in Diagnosis :\n",
            "If these cytopenia levels were used to diagnose MDS, 18% of MDS patients and 23%\n",
            "of those with <5% marrow blasts would lack any cytopenia and thus would not be\n",
            "classifiable as MDS.\n",
            "Using standard laboratory values for cytopenias (Hb <13 g/dL  [males], <12 g/dL\n",
            "[females], ANC <1.8 × 109/L, platelets <150 × 109/L), the data demonstrated that\n",
            "only 1.8% patients evaluated in that study of 7012 MDS subjects would lack a\n",
            "cytopenia (1.3% of patients when nonproliferative CMML  patients were excluded).2023, ICC classification of MPN\n",
            "*Most MPN patients are diagnosed in chronic phase (CP), which may progress into a blast\n",
            "phase (BP) associated with the accumulation of secondary cytogenetic and/or molecular\n",
            "aberrations\n",
            "------------------------------------------------------------\n",
            "Chunk #3, Size: 983\n",
            "Content: cytopenia (1.3% of patients when nonproliferative CMML  patients were excluded).2023, ICC classification of MPN\n",
            "*Most MPN patients are diagnosed in chronic phase (CP), which may progress into a blast\n",
            "phase (BP) associated with the accumulation of secondary cytogenetic and/or molecular\n",
            "aberrations\n",
            "2022 5th WHO classification (WHO-HAEM5): Chronic Myeloid\n",
            "Leukemia: Updated Risk Factors and PhasesChronic myeloid leukemia (cf. 2016 4th WHO: CML, BCR-ABL1-positive)\n",
            "Polycythemia vera\n",
            "Essential thrombocythemia\n",
            "Primary myelofibrosis\n",
            "Chronic neutrophilic leukemia\n",
            "Chronic eosinophilic leukemia\n",
            "Juvenile myelomonocytic leukemia (2016 4th WHO: MDS/MPN → 2022 5th WHO:\n",
            "MPN)\n",
            "Myeloproliferative neoplasm, not otherwise specified\n",
            "Chronic myeloid leukemia\n",
            "Polycythemia vera\n",
            "Essential thrombocythemia\n",
            "Primary myelofibrosis\n",
            "Early/prefibrotic primary myelofibrosis\n",
            "Overt primary myelofibrosis\n",
            "Chronic neutrophilic leukemia\n",
            "Chronic eosinophilic lelkemia, not otherwise specified\n",
            "MPN, unclassifiable\n",
            "------------------------------------------------------------\n",
            "Chunk #4, Size: 944\n",
            "Content: Chronic myeloid leukemia\n",
            "Polycythemia vera\n",
            "Essential thrombocythemia\n",
            "Primary myelofibrosis\n",
            "Early/prefibrotic primary myelofibrosis\n",
            "Overt primary myelofibrosis\n",
            "Chronic neutrophilic leukemia\n",
            "Chronic eosinophilic lelkemia, not otherwise specified\n",
            "MPN, unclassifiable\n",
            "Pediatric and/or germline mutation-associated disorders\n",
            "Juvenile myelomonocytic leukemia\n",
            "Juvenile myelomonocytic leukemia-like neoplasms\n",
            "Noonan syndrome-associated myeloproliferative disorder\n",
            "Refractory cytopenia of childhood\n",
            "Hematologic neoplasms with germline predisposition\n",
            "Chronic myeloid leukemia risk factors are refined, and accelerated phase is no longer\n",
            "required\n",
            "AP is omitted in the current classification in favor of an emphasis on high risk\n",
            "features associated with CP  progression and resistance to TKI\n",
            "10-year overall survival rate  with TKI therapy and careful disease monitoring: 80-\n",
            "90%**.2023 International Consensus Classification (ICC) Chronic\n",
            "Myeloid Leukemia\n",
            "------------------------------------------------------------\n",
            "Chunk #5, Size: 977\n",
            "Content: features associated with CP  progression and resistance to TKI\n",
            "10-year overall survival rate  with TKI therapy and careful disease monitoring: 80-\n",
            "90%**.2023 International Consensus Classification (ICC) Chronic\n",
            "Myeloid Leukemia\n",
            "The ICC has maintained a blast percentage threshold of 10% to 19% and at least 20% in the\n",
            "blood or BM to establish the diagnosis of AP and BP , respectively .\n",
            "2022 5th WHO classification (WHO-HAEM5): Changes to the\n",
            "Diagnostic Criteria of Chronic Eosinophilic Leukemia (CEL)\n",
            "Several significant changes have been made to the diagnostic criteria of Chronic\n",
            "Eosinophilic Leukemia (CEL), improving its distinction from other disorders with eosinophilia.\n",
            "These changes are:\n",
            "These modifications enhance the accuracy of diagnosing CEL, clearly dif ferentiating it from\n",
            "conditions like idiopathic hypereosinophilic syndrome and hypereosinophilia of unknown\n",
            "significance. Additionally , as the criteria of CEL  and its position relative to other eosinophilia\n",
            "------------------------------------------------------------\n",
            "Chunk #6, Size: 975\n",
            "Content: These changes are:\n",
            "These modifications enhance the accuracy of diagnosing CEL, clearly dif ferentiating it from\n",
            "conditions like idiopathic hypereosinophilic syndrome and hypereosinophilia of unknown\n",
            "significance. Additionally , as the criteria of CEL  and its position relative to other eosinophilia\n",
            "disorders have become more clearly defined, the qualifier \"not otherwise specified\" is no\n",
            "longer necessary and has been removed from the name.\n",
            "2023 International Consensus Classification; ICC\n",
            "Table 7. Diagnostic criteria for chronic eosinophilic leukemia, not otherwise specified\n",
            "(CEL, NOS)1. [Reduction of T ime Interval for Hypereosinophilia ]:\n",
            "The required time interval to define sustained hypereosinophilia is reduced from 6\n",
            "months to 4 weeks.\n",
            "2. [Clonality and Abnormal Bone Marrow Morphology Requirement ]:\n",
            "Addition of a requirement for both clonality and abnormal bone marrow morphology .\n",
            "Example of abnormal morphology includes megakaryocytic or erythroid dysplasia.\n",
            "------------------------------------------------------------\n",
            "Chunk #7, Size: 971\n",
            "Content: months to 4 weeks.\n",
            "2. [Clonality and Abnormal Bone Marrow Morphology Requirement ]:\n",
            "Addition of a requirement for both clonality and abnormal bone marrow morphology .\n",
            "Example of abnormal morphology includes megakaryocytic or erythroid dysplasia.\n",
            "3. [Elimination of Increased Blasts as an Alternative to Clonality ]:\n",
            "The criteria no longer consider increased blasts (>= 2% in peripheral blood or 5-19% in\n",
            "bone marrow) as an alternative to clonality .\n",
            "1. Penpheral blood hypereosinophilia (eosinophil count 1.5 x 10/L  and eosinophils 10%\n",
            "of white blood cells)\n",
            "2. Blasts constitute 20% cells in peripheral blood and bone marrow , not meeting other\n",
            "diagnostic criteria for AML\n",
            "3. No tyrosine kinase gene fusion including BCR-ABL1, other ABL1, PDGFRA,\n",
            "PDGFRB, FGFR1, JAK2, or FL T3 fusions2022 5th WHO classification (WHO-HAEM5): Juvenile\n",
            "Myelomonocytic Leukemia (JMML): An Overview\n",
            "Updates to Diagnostic Criteria for JMML\n",
            "Molecular Characteristics and Disease Aggressiveness\n",
            "------------------------------------------------------------\n",
            "Chunk #8, Size: 929\n",
            "Content: 3. No tyrosine kinase gene fusion including BCR-ABL1, other ABL1, PDGFRA,\n",
            "PDGFRB, FGFR1, JAK2, or FL T3 fusions2022 5th WHO classification (WHO-HAEM5): Juvenile\n",
            "Myelomonocytic Leukemia (JMML): An Overview\n",
            "Updates to Diagnostic Criteria for JMML\n",
            "Molecular Characteristics and Disease Aggressiveness\n",
            "Classification and Molecular Pathogenesis\n",
            "2023, ICC classification of JMML\n",
            "[Pediatric and/or germline mutation-associated disorders]4. Not meeting criteria for other well-defined MPN: chronic myelomonocytic leukemia, or\n",
            "SMT\n",
            "5. Bone marrow shows increased cellularity with dysplastic megakaryocytes with or\n",
            "without dysplastic features in other lineages and often significant fibrosis, associated\n",
            "with an eosinophilic infiltrate or increased blasts 5% in the bone marrow and/or ≥ 2%\n",
            "in the peripheral blood\n",
            "6. Demonstration of a clonal cytogenetic abnormality and/or somatic mutation(s)\n",
            "The diagnosis of CEL  requires all 6 criteria.\n",
            "------------------------------------------------------------\n",
            "Chunk #9, Size: 977\n",
            "Content: with an eosinophilic infiltrate or increased blasts 5% in the bone marrow and/or ≥ 2%\n",
            "in the peripheral blood\n",
            "6. Demonstration of a clonal cytogenetic abnormality and/or somatic mutation(s)\n",
            "The diagnosis of CEL  requires all 6 criteria.\n",
            "1. Exclusion of KMT2A  Rearrangements : KMT2A  rearrangements are no longer part of\n",
            "JMML  diagnostic criteria.\n",
            "2. Elimination of Monosomy 7 : Monosomy 7 has been removed as a cytogenetic\n",
            "criterion for JMML.\n",
            "3. Emphasis on Molecular Studies : Diagnostic criteria now emphasize the importance\n",
            "of molecular studies, particularly those demonstrating RAS pathway activation.\n",
            "Somatic Mutations and Germline V ariants : Cases initiated by somatic mutations\n",
            "involving [PTPN1 1] and germline pathogenic variants associated with\n",
            "[neurofibromatosis type 1] are considered the most [aggressive] types.\n",
            "Cases with [Germline CBL] V ariants : Some cases associated with pathogenic\n",
            "germline CBL  variants have been known to undergo [spontaneous remission].\n",
            "------------------------------------------------------------\n",
            "Chunk #10, Size: 994\n",
            "Content: involving [PTPN1 1] and germline pathogenic variants associated with\n",
            "[neurofibromatosis type 1] are considered the most [aggressive] types.\n",
            "Cases with [Germline CBL] V ariants : Some cases associated with pathogenic\n",
            "germline CBL  variants have been known to undergo [spontaneous remission].\n",
            "Inclusion under MPN : The inclusion of JMML  under the category of MPN reflects its\n",
            "molecular pathogenesis.\n",
            "Absence of Myelodysplastic Neoplasia Stigmata : There is a virtual absence of\n",
            "stigmata of bona fide myelodysplastic neoplasia in JMML, underscoring its unique\n",
            "disease characteristics.\n",
            "Juvenile myelomonocytic leukemia\n",
            "Juvenile myelomonocytic leukemia-like neoplasms\n",
            "Noonan syndrome-associated myeloproliferative disorderNote\n",
            "2016 4th WHO classification (WHO-HAEM4): Table 5.03 Diagnostic\n",
            "Criteria for Juvenile Myelomonocytic Leukaemia (Modified from\n",
            "Locatelli F and Niemeyer CM, 2377)\n",
            "Clinical and Haematological Criteria (All 4 Criteria Required)\n",
            "Genetic Criteria (Any 1 Criterion is Sufficient)\n",
            "------------------------------------------------------------\n",
            "Chunk #11, Size: 980\n",
            "Content: 2016 4th WHO classification (WHO-HAEM4): Table 5.03 Diagnostic\n",
            "Criteria for Juvenile Myelomonocytic Leukaemia (Modified from\n",
            "Locatelli F and Niemeyer CM, 2377)\n",
            "Clinical and Haematological Criteria (All 4 Criteria Required)\n",
            "Genetic Criteria (Any 1 Criterion is Sufficient)\n",
            "Other Criteria\n",
            "2022 5th WHO classification (WHO-HAEM5): Myelodysplastic\n",
            "Neoplasms (MDS): New Terminology and Grouping\n",
            "FrameworkRefractory cytopenia of childhood\n",
            "Hematologic neoplasms with germline predisposition\n",
            "Peripheral blood monocyte count ≥ 1 x 10^9/L\n",
            "Blast percentage in peripheral blood and bone marrow of < 20%\n",
            "Splenomegaly\n",
            "Absence of Philadelphia (Ph) chromosome or BCR-ABL1 fusion\n",
            "Somatic mutation in PTPN1 1, KRAS, or NRAS genes\n",
            "Clinical diagnosis of neurofibromatosis type 1 or NF1 mutation\n",
            "Germline CBL  mutation and loss of heterozygosity of CBL\n",
            "For cases not meeting any of the above genetic criteria, the following criteria must be\n",
            "met in addition to the clinical and haematological criteria:\n",
            "------------------------------------------------------------\n",
            "Chunk #12, Size: 981\n",
            "Content: Clinical diagnosis of neurofibromatosis type 1 or NF1 mutation\n",
            "Germline CBL  mutation and loss of heterozygosity of CBL\n",
            "For cases not meeting any of the above genetic criteria, the following criteria must be\n",
            "met in addition to the clinical and haematological criteria:\n",
            "Monosomy 7 or any other chromosomal abnormality\n",
            "At least 2 of the following:\n",
            "- Increased hemoglobin F percentage\n",
            "- Myeloid or erythroid precursors in peripheral blood smear\n",
            "- Granulocyte-macrophage colony-stimulating factor (GM-CSF , also called CSF2)\n",
            "hypersensitivity in colony assay\n",
            "- Hyperphosphorylation of ST AT5\n",
            "Note :\n",
            "If a mutation in PTPN1 1, KRAS, or NRAS is found, it is essential to consider that it\n",
            "might be a germline mutation. In such cases, the diagnosis of transient abnormal\n",
            "myelopoiesis of Noonan syndrome must be considered.\n",
            "Occasional cases have heterozygous splice-site mutationsTerminology Update\n",
            "Definition and Characteristics\n",
            "Grouping and Classification\n",
            "Risk Assessment and Classification\n",
            "------------------------------------------------------------\n",
            "Chunk #13, Size: 921\n",
            "Content: myelopoiesis of Noonan syndrome must be considered.\n",
            "Occasional cases have heterozygous splice-site mutationsTerminology Update\n",
            "Definition and Characteristics\n",
            "Grouping and Classification\n",
            "Risk Assessment and Classification\n",
            "2022 5th WHO classification (WHO-HAEM5): Classification\n",
            "and Defining Features of Myelodysplastic Neoplasms (MDS)\n",
            "[MDS with Defining Genetic Abnormalities]Introduction of \"Myelodysplastic Neoplasms (MDS)\" : The term 'myelodysplastic\n",
            "neoplasms' replaces the previous term 'myelodysplastic syndromes', highlighting their\n",
            "neoplastic nature.\n",
            "Alignment with MPN T erminology : The new term harmonizes the naming convention\n",
            "with myeloproliferative neoplasms (MPN).\n",
            "Clonal Hematopoietic Neoplasms :\n",
            "Key Features : Defined by cytopenias and morphologic dysplasia.\n",
            "Cytopenia Definitions : Adopted for consistency across clonal cytopenias of\n",
            "undetermined significance (CCUS), MDS, and MDS/MPN overlap syndromes.\n",
            "------------------------------------------------------------\n",
            "Chunk #14, Size: 968\n",
            "Content: with myeloproliferative neoplasms (MPN).\n",
            "Clonal Hematopoietic Neoplasms :\n",
            "Key Features : Defined by cytopenias and morphologic dysplasia.\n",
            "Cytopenia Definitions : Adopted for consistency across clonal cytopenias of\n",
            "undetermined significance (CCUS), MDS, and MDS/MPN overlap syndromes.\n",
            "Dysplasia Threshold : The threshold for dysplasia is standardized at 10% for all\n",
            "lineages.\n",
            "Genetic and Morphologic Grouping : MDS entities are now grouped into those with\n",
            "defining genetic abnormalities and those defined morphologically .\n",
            "Emphasis on Genetic Definitions : The reorganization prioritizes genetically-defined\n",
            "disease types.\n",
            "Shift from Risk-Based Grouping : Moves away from the previous emphasis on 'risk-\n",
            "based' grouping, which was based on blast percentage, ring sideroblasts, and the\n",
            "number of lineages with dysplasia.\n",
            "Adoption of Comprehensive Risk-Stratification Schemes : Recommends using\n",
            "more comprehensive schemes like the Revised International Prognostic Scoring\n",
            "------------------------------------------------------------\n",
            "Chunk #15, Size: 939\n",
            "Content: based' grouping, which was based on blast percentage, ring sideroblasts, and the\n",
            "number of lineages with dysplasia.\n",
            "Adoption of Comprehensive Risk-Stratification Schemes : Recommends using\n",
            "more comprehensive schemes like the Revised International Prognostic Scoring\n",
            "System for MDS (IPSS-R) for risk assessment.\n",
            "MDS with low blasts and isolated 5q deletion (MDS-5q)\n",
            "Blasts: <5% in BM and <2% in PB.\n",
            "Cytogenetics: 5q deletion alone, or with 1 other abnormality (excluding monosomy\n",
            "7 or 7q deletion).\n",
            "MDS with low blasts and SF3B1 mutation (MDS-SF3B1)\n",
            "Blasts: <5% in BM and <2% in PB.[MDS, Morphologically Defined]\n",
            "2023 ICC classification of MDSAbsence of 5q deletion, monosomy 7, or complex karyotype.\n",
            "Mutation: SF3B1.\n",
            "Detection of ≥15% ring sideroblasts may substitute for SF3B1 mutation.\n",
            "Acceptable related terminology: MDS with low blasts and ring sideroblasts.\n",
            "MDS with biallelic TP53 inactivation (MDS-biTP53)\n",
            "Blasts: <20% in BM and PB.\n",
            "------------------------------------------------------------\n",
            "Chunk #16, Size: 989\n",
            "Content: Mutation: SF3B1.\n",
            "Detection of ≥15% ring sideroblasts may substitute for SF3B1 mutation.\n",
            "Acceptable related terminology: MDS with low blasts and ring sideroblasts.\n",
            "MDS with biallelic TP53 inactivation (MDS-biTP53)\n",
            "Blasts: <20% in BM and PB.\n",
            "Mutation: Two or more TP53 mutations, or 1 mutation with evidence of TP53 copy\n",
            "number loss or copy-neutral loss of heterozygosity (cnLOH).\n",
            "**Classification Updates\n",
            "Single vs. Multilineage Dysplasia : The distinction between single lineage and\n",
            "multilineage dysplasia is now considered optional.\n",
            "Removal of MDS-U : The category 'MDS, unclassifiable' (MDS-U) is removed in\n",
            "this edition.\n",
            "MDS with low blasts (MDS-LB)\n",
            "Blasts: <5% in BM and <2% in PB.\n",
            "MDS, hypoplastic (MDS-h)\n",
            "By definition, ≤25% bone marrow cellularity , age adjusted.\n",
            "Immune Attack : Associated with T-cell mediated immune attack on hematopoietic\n",
            "stem and progenitor cells.\n",
            "Oligoclonal Expansion : Features oligoclonal expansion of CD8+ cytotoxic T-cells\n",
            "overproducing IFNy and/or TNFa.\n",
            "------------------------------------------------------------\n",
            "Chunk #17, Size: 996\n",
            "Content: By definition, ≤25% bone marrow cellularity , age adjusted.\n",
            "Immune Attack : Associated with T-cell mediated immune attack on hematopoietic\n",
            "stem and progenitor cells.\n",
            "Oligoclonal Expansion : Features oligoclonal expansion of CD8+ cytotoxic T-cells\n",
            "overproducing IFNy and/or TNFa.\n",
            "Overlap with PNH and AA: Shares several features with paroxysmal nocturnal\n",
            "hemoglobinuria (PNH) and aplastic anemia (AA), including an association with\n",
            "clonal hematopoiesis (CH).\n",
            "Germline Pathogenic V ariants : Individuals with germline pathogenic variants in\n",
            "genes like GA TA2, DDX41, Fanconi anemia (F A), or telomerase complex can\n",
            "have hypoplastic bone marrow .\n",
            "MDS with increased blasts (MDS-IB)\n",
            "MDS-IB1 : 5-9% BM or 2-4% PB.\n",
            "MDS-IB2 : 10-19% BM or 5-19% PB. Presence of Auer rods.\n",
            "MDS with fibrosis (MDS-f)\n",
            "Blasts: 5-19% in BM; 2-19% in PB.\n",
            "MDS with mutated SF3B1 (MDS- SF3B1)\n",
            "MDS with del(5q) [MDS-del(5q)]2022 5th WHO classification (WHO-HAEM5): Childhood\n",
            "Myelodysplastic Neoplasms: Updated Disease Terminology\n",
            "------------------------------------------------------------\n",
            "Chunk #18, Size: 990\n",
            "Content: MDS-IB2 : 10-19% BM or 5-19% PB. Presence of Auer rods.\n",
            "MDS with fibrosis (MDS-f)\n",
            "Blasts: 5-19% in BM; 2-19% in PB.\n",
            "MDS with mutated SF3B1 (MDS- SF3B1)\n",
            "MDS with del(5q) [MDS-del(5q)]2022 5th WHO classification (WHO-HAEM5): Childhood\n",
            "Myelodysplastic Neoplasms: Updated Disease Terminology\n",
            "Categories of Childhood MDS\n",
            "Key Considerations\n",
            "Risk Assessment and Prognosis\n",
            "2022 5th WHO classification (WHO-HAEM5):\n",
            "Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)MDS, NOS without dysplasia\n",
            "MDS, NOS with single lineage dysplasia\n",
            "MDS, NOS with multilineage dysplasia\n",
            "MDS with excess blasts (MDS-EB)\n",
            "MDS/AML\n",
            "1. Childhood MDS with Low Blasts (cMDS-LB)\n",
            "Bone Marrow (BM): <5%\n",
            "Peripheral Blood (PB): <2%\n",
            "Previously known as \"refractory cytopenia of childhood (RCC)\".\n",
            "type: Typically hypnocellular and not otherwise specified.\n",
            "2. Childhood MDS with Increased Blasts (cMDS-IB)\n",
            "BM: 5-19%\n",
            "PB: 2-19%\n",
            "More common to observe acquired cytogenetic abnormalities and RAS-pathway\n",
            "mutations compared to cMDS-LB.\n",
            "------------------------------------------------------------\n",
            "Chunk #19, Size: 966\n",
            "Content: Previously known as \"refractory cytopenia of childhood (RCC)\".\n",
            "type: Typically hypnocellular and not otherwise specified.\n",
            "2. Childhood MDS with Increased Blasts (cMDS-IB)\n",
            "BM: 5-19%\n",
            "PB: 2-19%\n",
            "More common to observe acquired cytogenetic abnormalities and RAS-pathway\n",
            "mutations compared to cMDS-LB.\n",
            "Exclusion of non-neoplastic causes of cytopenia, such as infections, nutritional\n",
            "deficiencies, metabolic diseases, bone marrow failure syndromes (BMFS), and\n",
            "germline pathogenic variants.\n",
            "Exclusion of juvenile myelomonocytic leukemia (JMML), myeloid proliferations\n",
            "associated with Down syndrome, and MDS post cytotoxic therapy from this group.\n",
            "Increased Risk of AML  Progression : Presence of monosomy 7, 7q deletion, or\n",
            "complex karyotype.\n",
            "Indolent Course : Normal karyotype or presence of trisomy 8.\n",
            "Prognostic Factors : Acquired cytogenetic abnormalities and RAS-pathway mutations\n",
            "are more prevalent in cMDS-IB, indicating a potential dif ference in disease progression\n",
            "------------------------------------------------------------\n",
            "Chunk #20, Size: 970\n",
            "Content: complex karyotype.\n",
            "Indolent Course : Normal karyotype or presence of trisomy 8.\n",
            "Prognostic Factors : Acquired cytogenetic abnormalities and RAS-pathway mutations\n",
            "are more prevalent in cMDS-IB, indicating a potential dif ference in disease progression\n",
            "and treatment response between cMDS-LB and cMDS-IB.Chronic Myelomonocytic Leukemia\n",
            "Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia\n",
            "Myelodysplastic/Myeloproliferative Neoplasm with SF3B1\n",
            "Mutation and Thrombocytosis\n",
            "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise\n",
            "Specified\n",
            "Transition from MDS/MPN to MPN\n",
            "Overview of 2023 ICC's Classification of MDS/MPN\n",
            "Subtypes of CMMLPreviously known as \"Atypical Chronic Myeloid Leukemia, BCR-ABL1-negative\" (4th\n",
            "WHO 2016).\n",
            "previously known as \"MDS/MPN with Ring Sideroblasts and Thrombocytosis (4th WHO\n",
            "2016)\n",
            "previously known as MDS/MPN, Unclassifiable (4th WHO 2016)\n",
            "Juvenile Myelomonocytic Leukemia\n",
            "1. Clonal Monocytosis of Undetermined Significance (CMUS)\n",
            "------------------------------------------------------------\n",
            "Chunk #21, Size: 966\n",
            "Content: WHO 2016).\n",
            "previously known as \"MDS/MPN with Ring Sideroblasts and Thrombocytosis (4th WHO\n",
            "2016)\n",
            "previously known as MDS/MPN, Unclassifiable (4th WHO 2016)\n",
            "Juvenile Myelomonocytic Leukemia\n",
            "1. Clonal Monocytosis of Undetermined Significance (CMUS)\n",
            "2. Clonal Cytopenia and Monocytosis of Undetermined Significance (CCMUS)\n",
            "3. Atypical Chronic Myeloid Leukemia (aCML)\n",
            "4. Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and\n",
            "Thrombocytosis (MDS/MPN-T -SF3B1)\n",
            "5. Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and\n",
            "Thrombocytosis, Not Otherwise Specified (MDS/MPN-RS-T , NOS)\n",
            "6. Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified\n",
            "(MDS/MPN, NOS)\n",
            "New Provisional Subentity: MDS/MPN with Isolated Isochromosome (17q)\n",
            "[MDS/MPN with i(17q)]\n",
            "This falls under the diagnostic umbrella of MDS/MPN, NOS and is characterized by a\n",
            "specific chromosomal abnormality (isochromosome 17q).2022 5th WHO classification (WHO-HAEM5): Chronic\n",
            "------------------------------------------------------------\n",
            "Chunk #22, Size: 962\n",
            "Content: (MDS/MPN, NOS)\n",
            "New Provisional Subentity: MDS/MPN with Isolated Isochromosome (17q)\n",
            "[MDS/MPN with i(17q)]\n",
            "This falls under the diagnostic umbrella of MDS/MPN, NOS and is characterized by a\n",
            "specific chromosomal abnormality (isochromosome 17q).2022 5th WHO classification (WHO-HAEM5): Chronic\n",
            "Myelomonocytic Leukemia (CMML): Diagnostic Criteria,\n",
            "Subtypes, and Blast-Based Subgrouping\n",
            "Diagnostic Criteria Refinement\n",
            "New Supporting Criterion\n",
            "Disease Subtypes\n",
            "Blast-Based Subgrouping\n",
            "2022 5th WHO classification (WHO-HAEM5): Acute Myeloid\n",
            "Leukemia (AML) with Defining Genetic Abnormalities\n",
            "AML with KMT2A RearrangementCutoff for Absolute Monocytosis : Lowered from 1.0 × 10^9/L  to 0.5 × 10^9/L. This\n",
            "change incorporates cases formerly classified as oligomonocytic CMML.\n",
            "When absolute monocytosis is ≥0.5×10^9/L  but <1.0×10^9/L, detection of one or\n",
            "more clonal cytogenetic or molecular abnormality and documentation of dysplasia\n",
            "in at least one lineage are required.\n",
            "------------------------------------------------------------\n",
            "Chunk #23, Size: 952\n",
            "Content: change incorporates cases formerly classified as oligomonocytic CMML.\n",
            "When absolute monocytosis is ≥0.5×10^9/L  but <1.0×10^9/L, detection of one or\n",
            "more clonal cytogenetic or molecular abnormality and documentation of dysplasia\n",
            "in at least one lineage are required.\n",
            "Abnormal Partitioning of Peripheral Blood Monocyte Subsets : Introduced as a new\n",
            "criterion.\n",
            "Notable increase in classical monocytes (>94%) in the absence of known active\n",
            "autoimmune diseases and/or systemic inflammatory syndromes.\n",
            "Myelodysplastic CMML  (MD-CMML) : Characterized by a WBC count < 13 × 10^9/L.\n",
            "Myeloproliferative CMML  (MP-CMML) : Defined by a WBC count ≥ 13 × 10^9/L.\n",
            "Commonly associated with activating RAS pathway mutations and adverse clinical\n",
            "outcomes.\n",
            "CMML-0 Subgroup  (<2% blasts in blood and <5% blasts in bone marrow) has been\n",
            "eliminated.\n",
            "The rationale is the evidence suggesting that the addition of this subgroup\n",
            "provides no or limited prognostic significance.\n",
            "------------------------------------------------------------\n",
            "Chunk #24, Size: 934\n",
            "Content: outcomes.\n",
            "CMML-0 Subgroup  (<2% blasts in blood and <5% blasts in bone marrow) has been\n",
            "eliminated.\n",
            "The rationale is the evidence suggesting that the addition of this subgroup\n",
            "provides no or limited prognostic significance.\n",
            "Definition Change : Now replaces \"AML  with t(9;1 1) (p22;q23); KMT2A-MLL T3\" (2016\n",
            "4th WHO classification).\n",
            "Common Fusion Partners : Over 80 KMT2A  partners identified, most common being\n",
            "MLLT3, AFDN, ELL, and MLL T10.\n",
            "Clinical Presentation in Adults : Often high blast counts, usually with monocytic\n",
            "differentiation.2023 International Consensus Classification (ICC)\n",
            "AML with NPM1 Mutation: Can be diagnosed irrespective of blast\n",
            "count, with emphasis on clinicopathologic correlation.\n",
            "AML with CEBPA Mutation\n",
            "RUNX1 Mutations in AML\n",
            "2022 5th WHO classification (WHO-HAEM5): Acute Myeloid\n",
            "Leukemia, Myelodysplasia-Related (AML-MR)\n",
            "Definition :\n",
            "Key Changes in AML-MR Diagnosis :Clinical Presentation in Children :\n",
            "------------------------------------------------------------\n",
            "Chunk #25, Size: 985\n",
            "Content: count, with emphasis on clinicopathologic correlation.\n",
            "AML with CEBPA Mutation\n",
            "RUNX1 Mutations in AML\n",
            "2022 5th WHO classification (WHO-HAEM5): Acute Myeloid\n",
            "Leukemia, Myelodysplasia-Related (AML-MR)\n",
            "Definition :\n",
            "Key Changes in AML-MR Diagnosis :Clinical Presentation in Children :\n",
            "AML with KMT2A::MLL T3 and KMT2A::MLL T10 often show megakaryoblastic\n",
            "differentiation.\n",
            "Low blast counts observed in bone marrow aspirate smears.\n",
            "AML  with t(9;1 1) (p21.3;q23.3)/MLL T3::KMT2A : ≥ 10% blast count.\n",
            "AML  with Other KMT2A  Rearrangements : ≥ 10% blast count.\n",
            "Definition Update : Includes both biallelic (biCEBP A) and single mutations in the basic\n",
            "leucine zipper (bZIP) region (smbZIP-CEВР А).\n",
            "Prognosis with smbZIP-CEBP A: Favorable prognosis demonstrated in children and\n",
            "adults up to 70 years old.\n",
            "Lack of Specificity : RUNX1 mutations overlap with a broad range of molecular\n",
            "features.\n",
            "Exclusion as a Standalone AML  Type: Due to lack of enough specificity to define a\n",
            "standalone AML type.\n",
            "------------------------------------------------------------\n",
            "Chunk #26, Size: 997\n",
            "Content: Prognosis with smbZIP-CEBP A: Favorable prognosis demonstrated in children and\n",
            "adults up to 70 years old.\n",
            "Lack of Specificity : RUNX1 mutations overlap with a broad range of molecular\n",
            "features.\n",
            "Exclusion as a Standalone AML  Type: Due to lack of enough specificity to define a\n",
            "standalone AML type.\n",
            "AML with myelodysplasia-related changes is now termed as AML, myelodysplasia-\n",
            "related (AML-MR).\n",
            "It is defined as a neoplasm with ≥20% blasts expressing a myeloid\n",
            "immunophenotype.\n",
            "Includes specific cytogenetic and molecular abnormalities associated with\n",
            "myelodysplastic syndromes (MDS).\n",
            "Can arise de novo or following a known history of MDS or MDS/myeloproliferative\n",
            "neoplasms (MDS/MPN).Diagnosis Requirements :\n",
            "2023International Consensus Classification (ICC): Defining\n",
            "Cytogenetic Abnormalities in Acute Myeloid Leukemia,\n",
            "Myelodysplasia-Related (AML-MR)\n",
            "Cytogenetic and Molecular Abnormalities1. Removal of Morphology-Based Diagnosis :\n",
            "Morphology alone is no longer a diagnostic premise for AML-MR.\n",
            "------------------------------------------------------------\n",
            "Chunk #27, Size: 934\n",
            "Content: 2023International Consensus Classification (ICC): Defining\n",
            "Cytogenetic Abnormalities in Acute Myeloid Leukemia,\n",
            "Myelodysplasia-Related (AML-MR)\n",
            "Cytogenetic and Molecular Abnormalities1. Removal of Morphology-Based Diagnosis :\n",
            "Morphology alone is no longer a diagnostic premise for AML-MR.\n",
            "2. Updated Cytogenetic Criteria :\n",
            "Cytogenetic criteria for diagnosing AML-MR have been updated.\n",
            "Complex Karyotype : Presence of three or more abnormalities.\n",
            "5q Deletion/Loss\n",
            "Monosomy 7 or 7q Deletion/Loss\n",
            "11q Deletion\n",
            "12p Deletion/Loss\n",
            "Monosomy 13 or 13q Deletion\n",
            "17p Deletion/Loss .\n",
            "Isochromosome 17q\n",
            "idic(X)(q13)\n",
            "3. Mutation-Based Definition :\n",
            "Introduction of a mutation-based definition involving a set of 8 genes:\n",
            "SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, ST AG2.\n",
            "Over 95% of these mutations are present specifically in AML arising post-MDS or\n",
            "MDS/MPN.\n",
            "The presence of one or more cytogenetic or molecular abnormalities defining AML-MR.\n",
            "------------------------------------------------------------\n",
            "Chunk #28, Size: 979\n",
            "Content: Introduction of a mutation-based definition involving a set of 8 genes:\n",
            "SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, ST AG2.\n",
            "Over 95% of these mutations are present specifically in AML arising post-MDS or\n",
            "MDS/MPN.\n",
            "The presence of one or more cytogenetic or molecular abnormalities defining AML-MR.\n",
            "And/or a history of MDS or MDS/MPN is required for diagnosing AML-MR.\n",
            "Gene Mutations in AML  and MDS/AML :\n",
            "Blasts 10-19% : Myelodysplastic Syndromes/Acute Myeloid Leukemia\n",
            "(MDS/AML)\n",
            "Blasts >= 20% : AML\n",
            "Defined by mutations in specific genes: ASXL1, BCOR, EZH2, [RUNX1],\n",
            "SF3B1, SRSF2, ST AG2, U2AF1, or ZRSR2.\n",
            "Specific chromosomal abnormalities:\n",
            "the detection of a complex karyotype, which includes three or more unrelated\n",
            "clonal chromosomal abnormalities in the absence of other class-defining2022 5th WHO classification (WHO-HAEM5): Secondary\n",
            "Myeloid Neoplasms\n",
            "Overview\n",
            "Classification and Grouping\n",
            "Redesign of Disease Framework\n",
            "Disease Attributesrecurring genetic abnormalities.\n",
            "------------------------------------------------------------\n",
            "Chunk #29, Size: 977\n",
            "Content: clonal chromosomal abnormalities in the absence of other class-defining2022 5th WHO classification (WHO-HAEM5): Secondary\n",
            "Myeloid Neoplasms\n",
            "Overview\n",
            "Classification and Grouping\n",
            "Redesign of Disease Framework\n",
            "Disease Attributesrecurring genetic abnormalities.\n",
            "Deletions and translocations involving chromosome 5 (del (5q)/t(5q)/add(5q))\n",
            "Chromosome 7 abnormalities (-7/del(7q))\n",
            "Trisomy 8 (+8)\n",
            "Chromosome 12 abnormalities (del(12p)/t(12p)/add(12p))\n",
            "Isodicentric chromosome 17 (i(17q))\n",
            "Chromosome 17 abnormalities (-17/add(17p) or del (17p))\n",
            "Deletion of chromosome 20q (del (20q))\n",
            "Isodicentric X chromosome (idic(X) (q13)) clonal abnormalities.\n",
            "Secondary myeloid neoplasms represent a newly segregated category .\n",
            "These diseases arise in the setting of known predisposing factors.\n",
            "Myeloid neoplasms that develop secondary to cytotoxic therapy or germline\n",
            "predisposition are included in this category .\n",
            "Acute Myeloid Leukemia (AML) transformation of Myeloproliferative Neoplasms (MPN)\n",
            "------------------------------------------------------------\n",
            "Chunk #30, Size: 992\n",
            "Content: These diseases arise in the setting of known predisposing factors.\n",
            "Myeloid neoplasms that develop secondary to cytotoxic therapy or germline\n",
            "predisposition are included in this category .\n",
            "Acute Myeloid Leukemia (AML) transformation of Myeloproliferative Neoplasms (MPN)\n",
            "is retained in the MPN category .\n",
            "AML transformation of Myelodysplastic Syndromes (MDS) and MDS/MPN is classified\n",
            "under AML with Myelodysplasia-Related Changes (AML-MR).\n",
            "The category's framework has been redesigned to incorporate:\n",
            "1. A scalable structure for novel discoveries in germline predisposition to myeloid\n",
            "neoplasia.\n",
            "2. Recognition of myeloid neoplasms following exposure to cytotoxic therapies for\n",
            "both clinical and population health purposes.\n",
            "Diseases are required to consider [\"post cytotoxic therapy\"] and [\"associated with\n",
            "germline (gene) variant]\" as key attributes.\n",
            "These attributes should be added as qualifiers to relevant myeloid disease types whose\n",
            "criteria are defined elsewhere in the classification.\n",
            "------------------------------------------------------------\n",
            "Chunk #31, Size: 972\n",
            "Content: Diseases are required to consider [\"post cytotoxic therapy\"] and [\"associated with\n",
            "germline (gene) variant]\" as key attributes.\n",
            "These attributes should be added as qualifiers to relevant myeloid disease types whose\n",
            "criteria are defined elsewhere in the classification.\n",
            "Examples: AML with KMT2A  rearrangement post cytotoxic therapy; MDS with low\n",
            "blasts associated with germline RUNX1 variant.Note on Lymphoblastic Leukemia/Lymphoma\n",
            "2023Diagnostic Qualifiers in ICC Table 26\n",
            "2022 5th WHO classification (WHO-HAEM5): Acute Leukemias\n",
            "of Mixed or Ambiguous Lineage (ALAL)\n",
            "Acute leukemia of ambiguous lineage (ALAL) and mixed-phenotype acute leukemia (MP AL)\n",
            "are categorized together due to their overlapping clinical and immunophenotypic features.\n",
            "They share common molecular pathogenic mechanisms, highlighting their complexity .\n",
            "MPAL with ZNF384 Rearrangement\n",
            "ALAL with BCL11B Rearrangement\n",
            "These findings demonstrate the intricate nature of ALAL  and MP AL, underlining the\n",
            "------------------------------------------------------------\n",
            "Chunk #32, Size: 952\n",
            "Content: They share common molecular pathogenic mechanisms, highlighting their complexity .\n",
            "MPAL with ZNF384 Rearrangement\n",
            "ALAL with BCL11B Rearrangement\n",
            "These findings demonstrate the intricate nature of ALAL  and MP AL, underlining the\n",
            "importance of precise diagnosis and understanding their molecular characteristics forLymphoblastic leukemia/lymphoma may also be therapy-related, and this association\n",
            "should be noted in the diagnosis.\n",
            "Specific Diagnostic Qualifiers for MDS, AML, or MDS/AML:\n",
            "[Therapy-related]: Prior chemotherapy , radiotherapy , immune interventions.\n",
            "[Progressing from MDS]: Confirmed by standard diagnostics.\n",
            "[Progressing from MDS/MPN (specify)]: Confirmed by standard diagnostics.\n",
            "Germline predisposition: Examples include AML with myelodysplasia-related\n",
            "cytogenetic abnormality , therapy-related; AML with myelodysplasia-related gene\n",
            "mutation, progressed from MDS; AML with myelodysplasia-related gene\n",
            "mutation, germline RUNX1 mutation.\n",
            "------------------------------------------------------------\n",
            "Chunk #33, Size: 997\n",
            "Content: Germline predisposition: Examples include AML with myelodysplasia-related\n",
            "cytogenetic abnormality , therapy-related; AML with myelodysplasia-related gene\n",
            "mutation, progressed from MDS; AML with myelodysplasia-related gene\n",
            "mutation, germline RUNX1 mutation.\n",
            "Immunophenotype : Commonly exhibits a B/myeloid immunophenotype.\n",
            "Prevalence : Identified in approximately 50% of pediatric B/myeloid MP AL.\n",
            "Fusion Partners : Includes TCF3, EP300, TAF15, and CREBBP .\n",
            "Transcriptional Profile : Shares a similar transcriptional profile with B-ALL, suggesting\n",
            "a biological continuum.\n",
            "Immunophenotype : More heterogenous compared to MP AL.\n",
            "Prevalence in AUL: Identified in acute undif ferentiated leukemia (AUL).\n",
            "Prevalence in MP AL: Found in about 20-30% of T/myeloid MP AL.\n",
            "BCL1 1B in Other Leukemias : Also identified in AML with minimal dif ferentiation or\n",
            "without maturation and approximately 20-30% of early T-cell precursor ALL (ETP-ALL),\n",
            "suggesting a biological continuum.effective treatment strategies.\n",
            "------------------------------------------------------------\n",
            "Chunk #34, Size: 990\n",
            "Content: Prevalence in MP AL: Found in about 20-30% of T/myeloid MP AL.\n",
            "BCL1 1B in Other Leukemias : Also identified in AML with minimal dif ferentiation or\n",
            "without maturation and approximately 20-30% of early T-cell precursor ALL (ETP-ALL),\n",
            "suggesting a biological continuum.effective treatment strategies.\n",
            "20225th WHO classification (WHO-HAEM5): Acute leukemias of\n",
            "ambiguous lineage (ALAL)\n",
            "2023 International Consensusu Classification (ICC): Acute\n",
            "leukemias of ambiguous lineage (ALAL)\n",
            "2024 5th WHO classification (WHO-HAEM5): Lineage\n",
            "Assignment Criteria for Mixed-Phenotype Acute Leukemia\n",
            "(IHC, flow cytometry)\n",
            "B LineageAcute leukemia of ambiguous lineage with defining genetic abnormalities\n",
            "Mixed-phenotype acute leukemia with BCR::ABL1 fusion\n",
            "Mixed-phenotype acute leukemia with KMT2A  rearrangement\n",
            "Acute leukemia of ambiguous lineage with other defined genetic alterations\n",
            "Mixed-phenotype acute leukemia with ZNF384 rearrangement\n",
            "Acute leukemia of ambiguous lineage with BCL1 1B rearrangement\n",
            "------------------------------------------------------------\n",
            "Chunk #35, Size: 996\n",
            "Content: Mixed-phenotype acute leukemia with KMT2A  rearrangement\n",
            "Acute leukemia of ambiguous lineage with other defined genetic alterations\n",
            "Mixed-phenotype acute leukemia with ZNF384 rearrangement\n",
            "Acute leukemia of ambiguous lineage with BCL1 1B rearrangement\n",
            "Acute leukemia of ambiguous lineage, immunophenotypically defined\n",
            "Mixed-phenotype acute leukemia, B/myeloid\n",
            "Mixed-phenotype acute leukemia, T/myeloid\n",
            "Mixed-phenotype acute leukemia, rare types\n",
            "Acute leukemia of ambiguous lineage, not otherwise specified\n",
            "Acute undif ferentiated leukemia\n",
            "Acute leukemia of ambiguous lineage\n",
            "Acute undif ferentiated leukemia\n",
            "Mixed phenotype acute leukemia (MP AL) with t(9;22)(q34.1;q1 1.2); BCR::ABL1\n",
            "MPAL, with t(v;1 1q23.3); KMT2A  rearranged\n",
            "MPAL, B/myeloid, NOS\n",
            "MPAL, T/myeloid, NOS\n",
            "[Strong CD19 Expression ]:\n",
            "Either CD19 is strongly expressed; CD19 intensity in part exceeds 50% of normal\n",
            "B cell progenitor level by flow cytometry\n",
            "Or, at least one of the following is also strongly expressed: CD10, CD22, or\n",
            "------------------------------------------------------------\n",
            "Chunk #36, Size: 990\n",
            "Content: MPAL, B/myeloid, NOS\n",
            "MPAL, T/myeloid, NOS\n",
            "[Strong CD19 Expression ]:\n",
            "Either CD19 is strongly expressed; CD19 intensity in part exceeds 50% of normal\n",
            "B cell progenitor level by flow cytometry\n",
            "Or, at least one of the following is also strongly expressed: CD10, CD22, or\n",
            "CD79a.T Lineage\n",
            "Myeloid Lineage\n",
            "2022 5th WHO classification (WHO-HAEM5): Genetic Tumor\n",
            "Syndromes with Predisposition to Myeloid Neoplasia\n",
            "Fanconi Anemia\n",
            "RASopathies[Weak CD19 Expression ]: CD19 intensity does not exceed 50% of normal B\n",
            "progenitor by flow cytometry\n",
            "Multiple Strong Expressions :\n",
            "Two or more of the following are strongly expressed: CD10, CD22, or CD79a.\n",
            "CD3 Expression (Cytoplasmic or Surface) :\n",
            "Intensity in part exceeds 50% of mature T-cells level by flow cytometry or\n",
            "immunocytochemistry positive with non-zeta chain reagent.\n",
            "Use of anti-CD3 epsilon chain antibody .\n",
            "Myeloperoxidase Expression :\n",
            "Either myeloperoxidase is present.\n",
            "Intensity Comparison : Intensity exceeds 50% of mature neutrophil level.\n",
            "------------------------------------------------------------\n",
            "Chunk #37, Size: 935\n",
            "Content: immunocytochemistry positive with non-zeta chain reagent.\n",
            "Use of anti-CD3 epsilon chain antibody .\n",
            "Myeloperoxidase Expression :\n",
            "Either myeloperoxidase is present.\n",
            "Intensity Comparison : Intensity exceeds 50% of mature neutrophil level.\n",
            "Or, evidence of monocytic dif ferentiation.\n",
            "Two or more of the following are expressed: Non-specific esterase, CD1 1c,\n",
            "CD14, CD64, or lysozyme.\n",
            "Cause : Germline variants in the BRCA-Fanconi DNA  repair pathway (involving ≥21\n",
            "genes).\n",
            "Effects : Results in chromosomal breakage and hypersensitivity to crosslinking agents\n",
            "used for diagnosis.\n",
            "Clinical Features : Congenital anomalies, bone marrow failure, and cancer\n",
            "predisposition.\n",
            "Hematologic Categories (5 T ypes) : Classified based on blast percentage, cytopenia,\n",
            "and chromosomal abnormalities.\n",
            "Key Indicators of Progression : Dysgranulopoiesis and dysmegakaryopoiesis in\n",
            "histology .\n",
            "Description : A diverse group of complex, multi-system disorders.\n",
            "------------------------------------------------------------\n",
            "Chunk #38, Size: 624\n",
            "Content: predisposition.\n",
            "Hematologic Categories (5 T ypes) : Classified based on blast percentage, cytopenia,\n",
            "and chromosomal abnormalities.\n",
            "Key Indicators of Progression : Dysgranulopoiesis and dysmegakaryopoiesis in\n",
            "histology .\n",
            "Description : A diverse group of complex, multi-system disorders.\n",
            "Genetic Basis : Variants in genes associated with the RAS mitogen-activating protein\n",
            "kinase (MAPK) pathway .\n",
            "Genes for Analysis : NF1, NRAS, KRAS, PTPN1 1, and CBL.Importance in Diagnosis : Genomic analysis of these genes is crucial for diagnosing\n",
            "myeloid neoplasms, especially juvenile myelomonocytic leukemia (JMML) in suspected\n",
            "cases.\n",
            "------------------------------------------------------------\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "마크다운을 동일하게 읽고 splitting하기\n"
      ],
      "metadata": {
        "id": "1JNYBl3yksso"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Markdown 파일 경로\n",
        "file_path = '/B3-summary-2022 5th WHO, 2023 ICC- myeloid.md'\n",
        "\n",
        "# Markdown 파일 읽기\n",
        "with open(file_path, 'r') as file:\n",
        "    markdown_content = file.read()\n",
        "\n"
      ],
      "metadata": {
        "id": "0y6yOdcXkww0"
      },
      "execution_count": 17,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# RecursiveCharacterTextSplitter로 텍스트 분할\n",
        "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=200)\n",
        "chunks = text_splitter.split_text(markdown_content)\n",
        "\n",
        "# 청크 개수, 크기 및 내용 출력\n",
        "print(f\"Total number of chunks: {len(chunks)}\")\n",
        "for i, chunk in enumerate(chunks):\n",
        "    chunk_size = len(chunk)\n",
        "    print(f\"Chunk #{i+1}, Size: {chunk_size}\")\n",
        "    print(\"Content:\", chunk)  # 청크 내용의 처음 500자만 출력 (내용이 긴 경우를 위해)\n",
        "    print(\"------------------------------------------------------------\")"
      ],
      "metadata": {
        "id": "z9RiQBGUkyDa"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import MarkdownTextSplitter\n",
        "\n",
        "\n",
        "markdown_splitter = MarkdownTextSplitter(chunk_size=800, chunk_overlap=300)\n",
        "chunks = markdown_splitter.create_documents([markdown_content])"
      ],
      "metadata": {
        "id": "jztlj-N-mgDh"
      },
      "execution_count": 32,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# 첫 번째 청크의 속성과 메소드 확인\n",
        "first_chunk = chunks[0]\n",
        "print(dir(first_chunk))\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vf2pH9uvo2md",
        "outputId": "69b1982b-314f-4d3d-a90c-fab2169f4033"
      },
      "execution_count": 28,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['Config', '__abstractmethods__', '__annotations__', '__class__', '__class_vars__', '__config__', '__custom_root_type__', '__delattr__', '__dict__', '__dir__', '__doc__', '__eq__', '__exclude_fields__', '__fields__', '__fields_set__', '__format__', '__ge__', '__get_validators__', '__getattribute__', '__getstate__', '__gt__', '__hash__', '__include_fields__', '__init__', '__init_subclass__', '__iter__', '__json_encoder__', '__le__', '__lt__', '__module__', '__ne__', '__new__', '__post_root_validators__', '__pre_root_validators__', '__pretty__', '__private_attributes__', '__reduce__', '__reduce_ex__', '__repr__', '__repr_args__', '__repr_name__', '__repr_str__', '__rich_repr__', '__schema_cache__', '__setattr__', '__setstate__', '__signature__', '__sizeof__', '__slots__', '__str__', '__subclasshook__', '__try_update_forward_refs__', '__validators__', '_abc_impl', '_calculate_keys', '_copy_and_set_values', '_decompose_class', '_enforce_dict_if_root', '_get_value', '_init_private_attributes', '_iter', '_lc_kwargs', 'construct', 'copy', 'dict', 'from_orm', 'get_lc_namespace', 'is_lc_serializable', 'json', 'lc_attributes', 'lc_id', 'lc_secrets', 'metadata', 'page_content', 'parse_file', 'parse_obj', 'parse_raw', 'schema', 'schema_json', 'to_json', 'to_json_not_implemented', 'type', 'update_forward_refs', 'validate']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "\n",
        "# 청크 개수, 크기 및 내용 출력\n",
        "print(f\"Total number of chunks: {len(chunks)}\")\n",
        "for i, chunk in enumerate(chunks):\n",
        "    chunk_text = chunk.page_content  # page_content 속성 사용\n",
        "    chunk_size = len(chunk_text)\n",
        "    print(f\"Chunk #{i+1}, Size: {chunk_size}\")\n",
        "    print(\"Content:\", chunk_text)\n",
        "    print(\"------------------------------------------------------------\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZvOpMQrymuAK",
        "outputId": "1616e5a0-65d7-4771-a19a-362accb305cb"
      },
      "execution_count": 33,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Total number of chunks: 58\n",
            "Chunk #1, Size: 289\n",
            "Content: #MDS #ICC #CMML #JMML\n",
            "### Cytopenia definitions 2022, 5th WHO classification (WHO-HAEM5)\n",
            "- Harmonized for CCUS, MDS, and MDS/MPN\n",
            "\t- Hb <13 g/dL in males and <12 g/dL in females for anemia -\n",
            "\t- Absolute neutrophil count <1.8×109/L for leukopenia\n",
            "\t- Platelets <150×109/L for thrombocytopenia\n",
            "------------------------------------------------------------\n",
            "Chunk #2, Size: 627\n",
            "Content: >[!note] ### Overview of 4th WHO 2016 Criteria (WHO-HAEM4) for Myelodysplastic Syndromes (MDS)\n",
            "> ##### Cytopenia Levels\n",
            "> **Definition**: Cytopenias are defined as follows:\n",
            "\t    >- Haemoglobin concentration < 10 g/dL\n",
            "\t    >- Platelet count < 100 x 10^9/L\n",
            "\t    >- Absolute neutrophil count (ANC) < 1.8 x 10^9/L\n",
            "> - **Peripheral Blood Monocytes**: Must be < 1 x 10^9/L.\n",
            ">##### Diagnostic Implications\n",
            ">- **Study Reference**: Greenberg PL, Tuechler H, Schanz J, et al. \"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.\" Blood 2016;128:2096-7.\n",
            ">- **Impact of Cytopenia Levels in Diagnosis**:\n",
            "------------------------------------------------------------\n",
            "Chunk #3, Size: 767\n",
            "Content: >##### Diagnostic Implications\n",
            ">- **Study Reference**: Greenberg PL, Tuechler H, Schanz J, et al. \"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.\" Blood 2016;128:2096-7.\n",
            ">- **Impact of Cytopenia Levels in Diagnosis**:\n",
            "  >  - If these cytopenia levels were used to diagnose MDS, 18% of MDS patients and 23% of those with <5% marrow blasts would lack any cytopenia and thus would not be classifiable as MDS.\n",
            ">- Using standard laboratory values for cytopenias (Hb <13 g/dL [males], <12 g/dL [females], ANC <1.8 × 109/L, platelets <150 × 109/L), the data demonstrated that only 1.8% patients evaluated in that study of 7012 MDS subjects would lack a cytopenia (1.3% of patients when nonproliferative CMML patients were excluded).\n",
            "------------------------------------------------------------\n",
            "Chunk #4, Size: 775\n",
            "Content: ### Classification of Myeloproliferative neoplasms (MPN) \n",
            "#### 2022, 5th WHO classification (WHO-HAEM5) of MPN\n",
            "- Chronic myeloid leukemia (cf. 2016 4th WHO: CML, BCR-ABL1-positive)\n",
            "- Polycythemia vera \n",
            "- Essential thrombocythemia \n",
            "- Primary myelofibrosis \n",
            "- Chronic neutrophilic leukemia \n",
            "- Chronic eosinophilic leukemia \n",
            "- Juvenile myelomonocytic leukemia (2016 4th WHO: MDS/MPN → 2022 5th WHO: MPN) \n",
            "- Myeloproliferative neoplasm, not otherwise specified\n",
            "#### 2023, ICC classification of MPN\n",
            "- Chronic myeloid leukemia\n",
            "- Polycythemia vera\n",
            "- Essential thrombocythemia\n",
            "- Primary myelofibrosis\n",
            "- Early/prefibrotic primary myelofibrosis\n",
            "- Overt primary myelofibrosis\n",
            "- Chronic neutrophilic leukemia\n",
            "- Chronic eosinophilic lelkemia, not otherwise specified\n",
            "- MPN, unclassifiable\n",
            "------------------------------------------------------------\n",
            "Chunk #5, Size: 575\n",
            "Content: - Chronic myeloid leukemia\n",
            "- Polycythemia vera\n",
            "- Essential thrombocythemia\n",
            "- Primary myelofibrosis\n",
            "- Early/prefibrotic primary myelofibrosis\n",
            "- Overt primary myelofibrosis\n",
            "- Chronic neutrophilic leukemia\n",
            "- Chronic eosinophilic lelkemia, not otherwise specified\n",
            "- MPN, unclassifiable\n",
            "- Pediatric and/or germline mutation-associated disorders\n",
            "\t- Juvenile myelomonocytic leukemia\n",
            "\t- Juvenile myelomonocytic leukemia-like neoplasms\n",
            "\t- Noonan syndrome-associated myeloproliferative disorder\n",
            "\t- Refractory cytopenia of childhood\n",
            "\t- Hematologic neoplasms with germline predisposition\n",
            "------------------------------------------------------------\n",
            "Chunk #6, Size: 627\n",
            "Content: *Most MPN patients are diagnosed in chronic phase (CP), which may progress into a blast phase (BP) associated with the accumulation of secondary cytogenetic and/or molecular aberrations\n",
            "\n",
            "### 2022 5th WHO classification (WHO-HAEM5): Chronic Myeloid Leukemia: Updated Risk Factors and Phases\n",
            "\n",
            "- Chronic myeloid leukemia risk factors are refined, and accelerated phase is no longer required\n",
            "- AP is omitted in the current classification in favor of an emphasis on high risk\n",
            "features associated with CP progression and resistance to TKI\n",
            "- 10-year overall survival rate** with TKI therapy and careful disease monitoring: **80-90%**.\n",
            "------------------------------------------------------------\n",
            "Chunk #7, Size: 551\n",
            "Content: ### 2023 International Consensus Classification (ICC) Chronic Myeloid Leukemia\n",
            "The ICC has maintained a blast percentage threshold of 10% to 19% and at least 20% in the blood or BM to establish the diagnosis of AP and BP, respectively.\n",
            "\n",
            "### 2022 5th WHO classification (WHO-HAEM5): Changes to the Diagnostic Criteria of Chronic Eosinophilic Leukemia (CEL)\n",
            "\n",
            "Several significant changes have been made to the diagnostic criteria of Chronic Eosinophilic Leukemia (CEL), improving its distinction from other disorders with eosinophilia. These changes are:\n",
            "------------------------------------------------------------\n",
            "Chunk #8, Size: 613\n",
            "Content: 1. [**Reduction of Time Interval for Hypereosinophilia**]:\n",
            "  - The required time interval to define sustained hypereosinophilia is reduced from 6 months to 4 weeks.\n",
            "2.  [**Clonality and Abnormal Bone Marrow Morphology Requirement**]:\n",
            "  - Addition of a requirement for both clonality and abnormal bone marrow morphology.\n",
            "  - Example of abnormal morphology includes megakaryocytic or erythroid dysplasia.\n",
            "3.  [**Elimination of Increased Blasts as an Alternative to Clonality**]:\n",
            "  - The criteria no longer consider increased blasts (>= 2% in peripheral blood or 5-19% in bone marrow) as an alternative to clonality.\n",
            "------------------------------------------------------------\n",
            "Chunk #9, Size: 420\n",
            "Content: These modifications enhance the accuracy of diagnosing CEL, clearly differentiating it from conditions like idiopathic hypereosinophilic syndrome and hypereosinophilia of unknown significance. Additionally, as the criteria of CEL and its position relative to other eosinophilia disorders have become more clearly defined, the qualifier \"not otherwise specified\" is no longer necessary and has been removed from the name.\n",
            "------------------------------------------------------------\n",
            "Chunk #10, Size: 585\n",
            "Content: >[!note] 2023 International Consensus Classification; ICC\n",
            "Table 7. Diagnostic criteria for chronic eosinophilic leukemia, not otherwise specified (CEL, NOS)\n",
            ">1. Penpheral blood hypereosinophilia (eosinophil count 1.5 x 10/L and eosinophils 10% of white blood cells)\n",
            ">2. Blasts constitute 20% cells in peripheral blood and bone marrow, not meeting other diagnostic criteria for AML\n",
            ">3. No tyrosine kinase gene fusion including BCR-ABL1, other ABL1, PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3 fusions\n",
            ">4. Not meeting criteria for other well-defined MPN: chronic myelomonocytic leukemia, or SMT\n",
            "------------------------------------------------------------\n",
            "Chunk #11, Size: 613\n",
            "Content: >3. No tyrosine kinase gene fusion including BCR-ABL1, other ABL1, PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3 fusions\n",
            ">4. Not meeting criteria for other well-defined MPN: chronic myelomonocytic leukemia, or SMT\n",
            ">5. Bone marrow shows increased cellularity with dysplastic megakaryocytes with or without dysplastic features in other lineages and often significant fibrosis, associated with an eosinophilic infiltrate or increased blasts 5% in the bone marrow and/or ≥ 2% in the peripheral blood\n",
            ">6. Demonstration of a clonal cytogenetic abnormality and/or somatic mutation(s)\n",
            "The diagnosis of CEL requires all 6 criteria.\n",
            "------------------------------------------------------------\n",
            "Chunk #12, Size: 519\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Juvenile Myelomonocytic Leukemia (JMML): An Overview\n",
            "\n",
            "#### Updates to Diagnostic Criteria for JMML\n",
            "1. **Exclusion of KMT2A Rearrangements**: KMT2A rearrangements are no longer part of JMML diagnostic criteria.\n",
            "2. **Elimination of Monosomy 7**: Monosomy 7 has been removed as a cytogenetic criterion for JMML.\n",
            "3. **Emphasis on Molecular Studies**: Diagnostic criteria now emphasize the importance of molecular studies, particularly those demonstrating RAS pathway activation.\n",
            "------------------------------------------------------------\n",
            "Chunk #13, Size: 783\n",
            "Content: #### Molecular Characteristics and Disease Aggressiveness\n",
            "- **Somatic Mutations and Germline Variants**: Cases initiated by somatic mutations involving [PTPN11] and germline pathogenic variants associated with [neurofibromatosis type 1] are considered the most [aggressive] types.\n",
            "- **Cases with [Germline CBL] Variants**: Some cases associated with pathogenic germline CBL variants have been known to undergo [spontaneous remission].\n",
            "\n",
            "#### Classification and Molecular Pathogenesis\n",
            "- **Inclusion under MPN**: The inclusion of JMML under the category of MPN reflects its molecular pathogenesis.\n",
            "- **Absence of Myelodysplastic Neoplasia Stigmata**: There is a virtual absence of stigmata of bona fide myelodysplastic neoplasia in JMML, underscoring its unique disease characteristics.\n",
            "------------------------------------------------------------\n",
            "Chunk #14, Size: 325\n",
            "Content: ### 2023, ICC classification of JMML\n",
            "[Pediatric and/or germline mutation-associated disorders]\n",
            "- Juvenile myelomonocytic leukemia\n",
            "- Juvenile myelomonocytic leukemia-like neoplasms\n",
            "- Noonan syndrome-associated myeloproliferative disorder\n",
            "- Refractory cytopenia of childhood\n",
            "- Hematologic neoplasms with germline predisposition\n",
            "------------------------------------------------------------\n",
            "Chunk #15, Size: 690\n",
            "Content: >[!note]\n",
            ">##### 2016 4th WHO classification (WHO-HAEM4): Table 5.03 Diagnostic Criteria for Juvenile Myelomonocytic Leukaemia (Modified from Locatelli F and Niemeyer CM, 2377)\n",
            ">##### Clinical and Haematological Criteria (All 4 Criteria Required)\n",
            ">- Peripheral blood monocyte count ≥ 1 x 10^9/L\n",
            ">- Blast percentage in peripheral blood and bone marrow of < 20%\n",
            ">- Splenomegaly \n",
            ">- Absence of Philadelphia (Ph) chromosome or BCR-ABL1 fusion\n",
            ">#### Genetic Criteria (Any 1 Criterion is Sufficient)\n",
            ">- Somatic mutation in PTPN11, KRAS, or NRAS genes\n",
            ">- Clinical diagnosis of neurofibromatosis type 1 or NF1 mutation\n",
            ">- Germline CBL mutation and loss of heterozygosity of CBL\n",
            ">##### Other Criteria\n",
            "------------------------------------------------------------\n",
            "Chunk #16, Size: 781\n",
            "Content: >#### Genetic Criteria (Any 1 Criterion is Sufficient)\n",
            ">- Somatic mutation in PTPN11, KRAS, or NRAS genes\n",
            ">- Clinical diagnosis of neurofibromatosis type 1 or NF1 mutation\n",
            ">- Germline CBL mutation and loss of heterozygosity of CBL\n",
            ">##### Other Criteria\n",
            ">- For cases not meeting any of the above genetic criteria, the following criteria must be met in addition to the clinical and haematological criteria:\n",
            "  >  - Monosomy 7 or any other chromosomal abnormality\n",
            "   > - At least 2 of the following:\n",
            "   >     - Increased hemoglobin F percentage\n",
            "   >     - Myeloid or erythroid precursors in peripheral blood smear\n",
            "   >     - Granulocyte-macrophage colony-stimulating factor (GM-CSF, also called CSF2) hypersensitivity in colony assay\n",
            "   >     - Hyperphosphorylation of STAT5\n",
            ">**Note**:\n",
            "------------------------------------------------------------\n",
            "Chunk #17, Size: 563\n",
            "Content: >     - Increased hemoglobin F percentage\n",
            "   >     - Myeloid or erythroid precursors in peripheral blood smear\n",
            "   >     - Granulocyte-macrophage colony-stimulating factor (GM-CSF, also called CSF2) hypersensitivity in colony assay\n",
            "   >     - Hyperphosphorylation of STAT5\n",
            ">**Note**:\n",
            ">- If a mutation in PTPN11, KRAS, or NRAS is found, it is essential to consider that it might be a germline mutation. In such cases, the diagnosis of transient abnormal myelopoiesis of Noonan syndrome must be considered.\n",
            ">- Occasional cases have heterozygous splice-site mutations\n",
            "------------------------------------------------------------\n",
            "Chunk #18, Size: 116\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Myelodysplastic Neoplasms (MDS): New Terminology and Grouping Framework\n",
            "------------------------------------------------------------\n",
            "Chunk #19, Size: 760\n",
            "Content: #### Terminology Update\n",
            "- **Introduction of \"Myelodysplastic Neoplasms (MDS)\"**: The term 'myelodysplastic neoplasms' replaces the previous term 'myelodysplastic syndromes', highlighting their neoplastic nature.\n",
            "- **Alignment with MPN Terminology**: The new term harmonizes the naming convention with myeloproliferative neoplasms (MPN).\n",
            "#### Definition and Characteristics\n",
            "- **Clonal Hematopoietic Neoplasms**: \n",
            "- **Key Features**: Defined by cytopenias and morphologic dysplasia.\n",
            "- **Cytopenia Definitions**: Adopted for consistency across clonal cytopenias of undetermined significance (CCUS), MDS, and MDS/MPN overlap syndromes.\n",
            "- **Dysplasia Threshold**: The threshold for dysplasia is standardized at 10% for all lineages.\n",
            "#### Grouping and Classification\n",
            "------------------------------------------------------------\n",
            "Chunk #20, Size: 776\n",
            "Content: - **Cytopenia Definitions**: Adopted for consistency across clonal cytopenias of undetermined significance (CCUS), MDS, and MDS/MPN overlap syndromes.\n",
            "- **Dysplasia Threshold**: The threshold for dysplasia is standardized at 10% for all lineages.\n",
            "#### Grouping and Classification\n",
            "- **Genetic and Morphologic Grouping**: MDS entities are now grouped into those with defining genetic abnormalities and those defined morphologically.\n",
            "- **Emphasis on Genetic Definitions**: The reorganization prioritizes genetically-defined disease types.\n",
            "#### Risk Assessment and Classification\n",
            "- **Shift from Risk-Based Grouping**: Moves away from the previous emphasis on 'risk-based' grouping, which was based on blast percentage, ring sideroblasts, and the number of lineages with dysplasia.\n",
            "------------------------------------------------------------\n",
            "Chunk #21, Size: 440\n",
            "Content: #### Risk Assessment and Classification\n",
            "- **Shift from Risk-Based Grouping**: Moves away from the previous emphasis on 'risk-based' grouping, which was based on blast percentage, ring sideroblasts, and the number of lineages with dysplasia.\n",
            "- **Adoption of Comprehensive Risk-Stratification Schemes**: Recommends using more comprehensive schemes like the Revised International Prognostic Scoring System for MDS (IPSS-R) for risk assessment.\n",
            "------------------------------------------------------------\n",
            "Chunk #22, Size: 786\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Classification and Defining Features of Myelodysplastic Neoplasms (MDS)\n",
            "#### [MDS with Defining Genetic Abnormalities]\n",
            "- **MDS with low blasts and isolated 5q deletion (MDS-5q)**\n",
            "\t  - Blasts: <5% in BM and <2% in PB.\n",
            "\t  - Cytogenetics: 5q deletion alone, or with 1 other abnormality (excluding monosomy 7 or 7q deletion).\n",
            "- **MDS with low blasts and SF3B1 mutation (MDS-SF3B1)**\n",
            "\t  - Blasts: <5% in BM and <2% in PB.\n",
            "\t  - Absence of 5q deletion, monosomy 7, or complex karyotype.\n",
            "\t  - Mutation: SF3B1.\n",
            "\t  - Detection of ≥15% ring sideroblasts may substitute for SF3B1 mutation. Acceptable related terminology: MDS with low blasts and ring sideroblasts. \n",
            "- **MDS with biallelic TP53 inactivation (MDS-biTP53)**\n",
            "\t  - Blasts: <20% in BM and PB.\n",
            "------------------------------------------------------------\n",
            "Chunk #23, Size: 770\n",
            "Content: - Mutation: SF3B1.\n",
            "\t  - Detection of ≥15% ring sideroblasts may substitute for SF3B1 mutation. Acceptable related terminology: MDS with low blasts and ring sideroblasts. \n",
            "- **MDS with biallelic TP53 inactivation (MDS-biTP53)**\n",
            "\t  - Blasts: <20% in BM and PB.\n",
            "\t  - Mutation: Two or more TP53 mutations, or 1 mutation with evidence of TP53 copy number loss or copy-neutral loss of heterozygosity (cnLOH).\n",
            "#### [MDS, Morphologically Defined]\n",
            "- **Classification Updates\n",
            "\t- **Single vs. Multilineage Dysplasia**: The distinction between single lineage and multilineage dysplasia is now considered optional.\n",
            "\t- **Removal of MDS-U**: The category 'MDS, unclassifiable' (MDS-U) is removed in this edition.\n",
            "- **MDS with low blasts (MDS-LB)**\n",
            "\t  - Blasts: <5% in BM and <2% in PB.\n",
            "------------------------------------------------------------\n",
            "Chunk #24, Size: 677\n",
            "Content: - **Removal of MDS-U**: The category 'MDS, unclassifiable' (MDS-U) is removed in this edition.\n",
            "- **MDS with low blasts (MDS-LB)**\n",
            "\t  - Blasts: <5% in BM and <2% in PB.\n",
            "- **MDS, hypoplastic (MDS-h)**\n",
            "\t- By definition, ≤25% bone marrow cellularity, age adjusted.\n",
            "\t- **Immune Attack**: Associated with T-cell mediated immune attack on hematopoietic stem and progenitor cells.\n",
            "\t- **Oligoclonal Expansion**: Features oligoclonal expansion of CD8+ cytotoxic T-cells overproducing IFNy and/or TNFa.\n",
            "\t- **Overlap with PNH and AA**: Shares several features with paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA), including an association with clonal hematopoiesis (CH).\n",
            "------------------------------------------------------------\n",
            "Chunk #25, Size: 585\n",
            "Content: - **Overlap with PNH and AA**: Shares several features with paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA), including an association with clonal hematopoiesis (CH).\n",
            "\t- **Germline Pathogenic Variants**: Individuals with germline pathogenic variants in genes like GATA2, DDX41, Fanconi anemia (FA), or telomerase complex can have hypoplastic bone marrow.\n",
            "- **MDS with increased blasts (MDS-IB)**\n",
            "\t  - **MDS-IB1**: 5-9% BM or 2-4% PB.\n",
            "\t  - **MDS-IB2**: 10-19% BM or 5-19% PB. Presence of Auer rods.\n",
            "- **MDS with fibrosis (MDS-f)**\n",
            "  - Blasts: 5-19% in BM; 2-19% in PB.\n",
            "------------------------------------------------------------\n",
            "Chunk #26, Size: 385\n",
            "Content: >[!note] ### 2023 ICC classification of MDS\n",
            ">- MDS with mutated SF3B1 (MDS- SF3B1)\n",
            ">- MDS with del(5q) [MDS-del(5q)]\n",
            ">- MDS, NOS without dysplasia\n",
            ">- MDS, NOS with single lineage dysplasia\n",
            ">- MDS, NOS with multilineage dysplasia\n",
            ">- MDS with excess blasts (MDS-EB)\n",
            ">- MDS/AML\n",
            "\n",
            "### 2022 5th WHO classification (WHO-HAEM5): Childhood Myelodysplastic Neoplasms: Updated Disease Terminology\n",
            "------------------------------------------------------------\n",
            "Chunk #27, Size: 683\n",
            "Content: #### Categories of Childhood MDS\n",
            "1. **Childhood MDS with Low Blasts (cMDS-LB)**\n",
            "    - Bone Marrow (BM): <5%\n",
            "    - Peripheral Blood (PB): <2%\n",
            "    - Previously known as \"refractory cytopenia of childhood (RCC)\".\n",
            "    - type: Typically hypnocellular and not otherwise specified.\n",
            "2. **Childhood MDS with Increased Blasts (cMDS-IB)**\n",
            "    - BM: 5-19%\n",
            "    - PB: 2-19%\n",
            "    - More common to observe acquired cytogenetic abnormalities and RAS-pathway mutations compared to cMDS-LB.\n",
            "#### Key Considerations\n",
            "- Exclusion of non-neoplastic causes of cytopenia, such as infections, nutritional deficiencies, metabolic diseases, bone marrow failure syndromes (BMFS), and germline pathogenic variants.\n",
            "------------------------------------------------------------\n",
            "Chunk #28, Size: 798\n",
            "Content: #### Key Considerations\n",
            "- Exclusion of non-neoplastic causes of cytopenia, such as infections, nutritional deficiencies, metabolic diseases, bone marrow failure syndromes (BMFS), and germline pathogenic variants.\n",
            "- Exclusion of juvenile myelomonocytic leukemia (JMML), myeloid proliferations associated with Down syndrome, and MDS post cytotoxic therapy from this group.\n",
            "#### Risk Assessment and Prognosis\n",
            "- **Increased Risk of AML Progression**: Presence of monosomy 7, 7q deletion, or complex karyotype.\n",
            "- **Indolent Course**: Normal karyotype or presence of trisomy 8.\n",
            "- **Prognostic Factors**: Acquired cytogenetic abnormalities and RAS-pathway mutations are more prevalent in cMDS-IB, indicating a potential difference in disease progression and treatment response between cMDS-LB and cMDS-IB.\n",
            "------------------------------------------------------------\n",
            "Chunk #29, Size: 680\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)\n",
            "\n",
            "#### Chronic Myelomonocytic Leukemia \n",
            "#### Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia\n",
            "- Previously known as \"Atypical Chronic Myeloid Leukemia, BCR-ABL1-negative\" (4th WHO 2016).\n",
            "#### Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis\n",
            "- previously known as \"MDS/MPN with Ring Sideroblasts and Thrombocytosis (4th WHO 2016)\n",
            "#### Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified\n",
            "- previously known as MDS/MPN, Unclassifiable (4th WHO 2016)\n",
            "#### Transition from MDS/MPN to MPN\n",
            "- Juvenile Myelomonocytic Leukemia\n",
            "------------------------------------------------------------\n",
            "Chunk #30, Size: 716\n",
            "Content: >[!note] ### Overview of 2023 ICC's Classification of MDS/MPN \n",
            ">#### Subtypes of CMML\n",
            ">1. **Clonal Monocytosis of Undetermined Significance (CMUS)**  \n",
            ">2. **Clonal Cytopenia and Monocytosis of Undetermined Significance (CCMUS)**\n",
            ">3. **Atypical Chronic Myeloid Leukemia (aCML)**\n",
            ">4. **Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis (MDS/MPN-T-SF3B1)**\n",
            ">5. **Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified (MDS/MPN-RS-T, NOS)**\n",
            ">6. **Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified (MDS/MPN, NOS)**\n",
            " >- **New Provisional Subentity: MDS/MPN with Isolated Isochromosome (17q) [MDS/MPN with i(17q)]**\n",
            "------------------------------------------------------------\n",
            "Chunk #31, Size: 331\n",
            "Content: >6. **Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified (MDS/MPN, NOS)**\n",
            " >- **New Provisional Subentity: MDS/MPN with Isolated Isochromosome (17q) [MDS/MPN with i(17q)]**\n",
            " >- This falls under the diagnostic umbrella of MDS/MPN, NOS and is characterized by a specific chromosomal abnormality (isochromosome 17q).\n",
            "------------------------------------------------------------\n",
            "Chunk #32, Size: 143\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Chronic Myelomonocytic Leukemia (CMML): Diagnostic Criteria, Subtypes, and Blast-Based Subgrouping\n",
            "------------------------------------------------------------\n",
            "Chunk #33, Size: 769\n",
            "Content: #### Diagnostic Criteria Refinement\n",
            "- **Cutoff for Absolute Monocytosis**: Lowered from 1.0 × 10^9/L to 0.5 × 10^9/L. This change incorporates cases formerly classified as oligomonocytic CMML.\n",
            "    - When absolute monocytosis is ≥0.5×10^9/L but <1.0×10^9/L, detection of one or more clonal cytogenetic or molecular abnormality and documentation of dysplasia in at least one lineage are required.\n",
            "#### New Supporting Criterion\n",
            "- **Abnormal Partitioning of Peripheral Blood Monocyte Subsets**: Introduced as a new criterion.\n",
            "    - Notable increase in classical monocytes (>94%) in the absence of known active autoimmune diseases and/or systemic inflammatory syndromes.\n",
            "#### Disease Subtypes\n",
            "- **Myelodysplastic CMML (MD-CMML)**: Characterized by a WBC count < 13 × 10^9/L.\n",
            "------------------------------------------------------------\n",
            "Chunk #34, Size: 671\n",
            "Content: - Notable increase in classical monocytes (>94%) in the absence of known active autoimmune diseases and/or systemic inflammatory syndromes.\n",
            "#### Disease Subtypes\n",
            "- **Myelodysplastic CMML (MD-CMML)**: Characterized by a WBC count < 13 × 10^9/L.\n",
            "- **Myeloproliferative CMML (MP-CMML)**: Defined by a WBC count ≥ 13 × 10^9/L.\n",
            "    - Commonly associated with activating RAS pathway mutations and adverse clinical outcomes.\n",
            "#### Blast-Based Subgrouping\n",
            "- **CMML-0 Subgroup** (<2% blasts in blood and <5% blasts in bone marrow) has been eliminated.\n",
            "    - The rationale is the evidence suggesting that the addition of this subgroup provides no or limited prognostic significance.\n",
            "------------------------------------------------------------\n",
            "Chunk #35, Size: 664\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Acute Myeloid Leukemia (AML) with Defining Genetic Abnormalities\n",
            "\n",
            "#### AML with KMT2A Rearrangement\n",
            "- **Definition Change**: Now replaces \"AML with t(9;11) (p22;q23); KMT2A-MLLT3\" (2016 4th WHO classification).\n",
            "- **Common Fusion Partners**: Over 80 KMT2A partners identified, most common being MLLT3, AFDN, ELL, and MLLT10.\n",
            "- **Clinical Presentation in Adults**: Often high blast counts, usually with monocytic differentiation.\n",
            "- **Clinical Presentation in Children**:\n",
            "  - AML with KMT2A::MLLT3 and KMT2A::MLLT10 often show megakaryoblastic differentiation.\n",
            "  - Low blast counts observed in bone marrow aspirate smears.\n",
            "------------------------------------------------------------\n",
            "Chunk #36, Size: 326\n",
            "Content: >[!note] #### 2023 International Consensus Classification  (ICC)\n",
            ">- **AML with t(9;11) (p21.3;q23.3)/MLLT3::KMT2A**: ≥ 10% blast count.\n",
            ">- **AML with Other KMT2A Rearrangements**: ≥ 10% blast count.\n",
            "\n",
            "#### **AML with NPM1 Mutation**: Can be diagnosed irrespective of blast count, with emphasis on clinicopathologic correlation.\n",
            "------------------------------------------------------------\n",
            "Chunk #37, Size: 737\n",
            "Content: #### **AML with NPM1 Mutation**: Can be diagnosed irrespective of blast count, with emphasis on clinicopathologic correlation.\n",
            "\n",
            "#### AML with CEBPA Mutation\n",
            "- **Definition Update**: Includes both biallelic (biCEBPA) and single mutations in the basic leucine zipper (bZIP) region (smbZIP-CEВРА).\n",
            "- **Prognosis with smbZIP-CEBPA**: Favorable prognosis demonstrated in children and adults up to 70 years old.\n",
            "#### RUNX1 Mutations in AML\n",
            "- **Lack of Specificity**: RUNX1 mutations overlap with a broad range of molecular features.\n",
            "- **Exclusion as a Standalone AML Type**: Due to lack of enough specificity to define a standalone AML type.\n",
            "\n",
            "### 2022 5th WHO classification (WHO-HAEM5): Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR)\n",
            "------------------------------------------------------------\n",
            "Chunk #38, Size: 514\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR)\n",
            "\n",
            "**Definition**:\n",
            "- AML with myelodysplasia-related changes is now termed as AML, myelodysplasia-related (AML-MR).\n",
            "\t- It is defined as a neoplasm with ≥20% blasts expressing a myeloid immunophenotype.\n",
            "\t- Includes specific cytogenetic and molecular abnormalities associated with myelodysplastic syndromes (MDS).\n",
            "\t- Can arise de novo or following a known history of MDS or MDS/myeloproliferative neoplasms (MDS/MPN).\n",
            "------------------------------------------------------------\n",
            "Chunk #39, Size: 706\n",
            "Content: **Key Changes in AML-MR Diagnosis**:\n",
            "1. **Removal of Morphology-Based Diagnosis**:\n",
            "   - Morphology alone is no longer a diagnostic premise for AML-MR.\n",
            "2. **Updated Cytogenetic Criteria**:\n",
            "   - Cytogenetic criteria for diagnosing AML-MR have been updated.\n",
            "\t- **Complex Karyotype**: Presence of three or more abnormalities.\n",
            "\t- **5q Deletion/Loss**\n",
            "\t- **Monosomy 7 or 7q Deletion/Loss**\n",
            "\t- **11q Deletion**\n",
            "\t- **12p Deletion/Loss**\n",
            "\t- **Monosomy 13 or 13q Deletion**\n",
            "\t- **17p Deletion/Loss**.\n",
            "\t- **Isochromosome 17q**\n",
            "\t- **idic(X)(q13)**\n",
            "1. **Mutation-Based Definition**:\n",
            "   - Introduction of a mutation-based definition involving a set of 8 genes:\n",
            "     - SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, STAG2.\n",
            "------------------------------------------------------------\n",
            "Chunk #40, Size: 370\n",
            "Content: - **Monosomy 13 or 13q Deletion**\n",
            "\t- **17p Deletion/Loss**.\n",
            "\t- **Isochromosome 17q**\n",
            "\t- **idic(X)(q13)**\n",
            "1. **Mutation-Based Definition**:\n",
            "   - Introduction of a mutation-based definition involving a set of 8 genes:\n",
            "     - SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, STAG2.\n",
            "   - Over 95% of these mutations are present specifically in AML arising post-MDS or MDS/MPN.\n",
            "------------------------------------------------------------\n",
            "Chunk #41, Size: 186\n",
            "Content: **Diagnosis Requirements**: \n",
            "- The presence of one or more cytogenetic or molecular abnormalities defining AML-MR.\n",
            "- And/or a history of MDS or MDS/MPN is required for diagnosing AML-MR.\n",
            "------------------------------------------------------------\n",
            "Chunk #42, Size: 795\n",
            "Content: >[!note] ### 2023International Consensus Classification (ICC): Defining Cytogenetic Abnormalities in Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR)\n",
            ">##### Cytogenetic and Molecular Abnormalities\n",
            ">- **Gene Mutations in AML and MDS/AML**:\n",
            "    >\t- Blasts 10-19% : Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) \n",
            "    >\t- Blasts >= 20% : AML\n",
            "    >\t- Defined by mutations in specific genes: ASXL1, BCOR, EZH2, [RUNX1], SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2.\n",
            "> - Specific chromosomal abnormalities:\n",
            "> \n",
            "        >\t- the detection of a complex karyotype, which includes three or more unrelated clonal chromosomal abnormalities in the absence of other class-defining recurring genetic abnormalities.\t\n",
            "\t\t>    - Deletions and translocations involving chromosome 5 (del (5q)/t(5q)/add(5q))\n",
            "------------------------------------------------------------\n",
            "Chunk #43, Size: 672\n",
            "Content: > \n",
            "        >\t- the detection of a complex karyotype, which includes three or more unrelated clonal chromosomal abnormalities in the absence of other class-defining recurring genetic abnormalities.\t\n",
            "\t\t>    - Deletions and translocations involving chromosome 5 (del (5q)/t(5q)/add(5q))\n",
            "        >\t- Chromosome 7 abnormalities (-7/del(7q))\n",
            "        >\t- Trisomy 8 (+8)\n",
            "        >\t- Chromosome 12 abnormalities (del(12p)/t(12p)/add(12p))\n",
            "        >\t- Isodicentric chromosome 17 (i(17q))\n",
            "        >\t- Chromosome 17 abnormalities (-17/add(17p) or del (17p))\n",
            "        >\t- Deletion of chromosome 20q (del (20q))\n",
            "        >\t- Isodicentric X chromosome (idic(X) (q13)) clonal abnormalities.\n",
            "------------------------------------------------------------\n",
            "Chunk #44, Size: 72\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Secondary Myeloid Neoplasms\n",
            "------------------------------------------------------------\n",
            "Chunk #45, Size: 756\n",
            "Content: #### Overview\n",
            "- Secondary myeloid neoplasms represent a newly segregated category.\n",
            "- These diseases arise in the setting of known predisposing factors.\n",
            "#### Classification and Grouping\n",
            "- Myeloid neoplasms that develop secondary to cytotoxic therapy or germline predisposition are included in this category.\n",
            "- Acute Myeloid Leukemia (AML) transformation of Myeloproliferative Neoplasms (MPN) is retained in the MPN category.\n",
            "- AML transformation of Myelodysplastic Syndromes (MDS) and MDS/MPN is classified under AML with Myelodysplasia-Related Changes (AML-MR).\n",
            "#### Redesign of Disease Framework\n",
            "- The category's framework has been redesigned to incorporate:\n",
            "  1. A scalable structure for novel discoveries in germline predisposition to myeloid neoplasia.\n",
            "------------------------------------------------------------\n",
            "Chunk #46, Size: 791\n",
            "Content: #### Redesign of Disease Framework\n",
            "- The category's framework has been redesigned to incorporate:\n",
            "  1. A scalable structure for novel discoveries in germline predisposition to myeloid neoplasia.\n",
            "  2. Recognition of myeloid neoplasms following exposure to cytotoxic therapies for both clinical and population health purposes.\n",
            "#### Disease Attributes\n",
            "- Diseases are required to consider [\"post cytotoxic therapy\"] and [\"associated with germline (gene) variant]\" as key attributes.\n",
            "- These attributes should be added as qualifiers to relevant myeloid disease types whose criteria are defined elsewhere in the classification.\n",
            "- Examples: AML with KMT2A rearrangement post cytotoxic therapy; MDS with low blasts associated with germline RUNX1 variant.\n",
            "#### Note on Lymphoblastic Leukemia/Lymphoma\n",
            "------------------------------------------------------------\n",
            "Chunk #47, Size: 287\n",
            "Content: - Examples: AML with KMT2A rearrangement post cytotoxic therapy; MDS with low blasts associated with germline RUNX1 variant.\n",
            "#### Note on Lymphoblastic Leukemia/Lymphoma\n",
            "- Lymphoblastic leukemia/lymphoma may also be therapy-related, and this association should be noted in the diagnosis.\n",
            "------------------------------------------------------------\n",
            "Chunk #48, Size: 704\n",
            "Content: >[!note]  #### 2023Diagnostic Qualifiers in ICC Table 26\n",
            ">- Specific Diagnostic Qualifiers for MDS, AML, or MDS/AML:\n",
            "  >\t- [Therapy-related]: Prior chemotherapy, radiotherapy, immune interventions.\n",
            "  >\t- [Progressing from MDS]: Confirmed by standard diagnostics.\n",
            "  >\t- [Progressing from MDS/MPN (specify)]: Confirmed by standard diagnostics.\n",
            "  >\t- Germline predisposition: Examples include AML with myelodysplasia-related cytogenetic abnormality, therapy-related; AML with myelodysplasia-related gene mutation, progressed from MDS; AML with myelodysplasia-related gene mutation, germline RUNX1 mutation.\n",
            "  \n",
            "### 2022 5th WHO classification (WHO-HAEM5): Acute Leukemias of Mixed or Ambiguous Lineage (ALAL)\n",
            "------------------------------------------------------------\n",
            "Chunk #49, Size: 797\n",
            "Content: Acute leukemia of ambiguous lineage (ALAL) and mixed-phenotype acute leukemia (MPAL) are categorized together due to their overlapping clinical and immunophenotypic features. They share common molecular pathogenic mechanisms, highlighting their complexity.\n",
            "#### MPAL with ZNF384 Rearrangement\n",
            "- **Immunophenotype**: Commonly exhibits a B/myeloid immunophenotype.\n",
            "- **Prevalence**: Identified in approximately 50% of pediatric B/myeloid MPAL.\n",
            "- **Fusion Partners**: Includes TCF3, EP300, TAF15, and CREBBP.\n",
            "- **Transcriptional Profile**: Shares a similar transcriptional profile with B-ALL, suggesting a biological continuum.\n",
            "#### ALAL with BCL11B Rearrangement\n",
            "- **Immunophenotype**: More heterogenous compared to MPAL.\n",
            "- **Prevalence in AUL**: Identified in acute undifferentiated leukemia (AUL).\n",
            "------------------------------------------------------------\n",
            "Chunk #50, Size: 566\n",
            "Content: - **Transcriptional Profile**: Shares a similar transcriptional profile with B-ALL, suggesting a biological continuum.\n",
            "#### ALAL with BCL11B Rearrangement\n",
            "- **Immunophenotype**: More heterogenous compared to MPAL.\n",
            "- **Prevalence in AUL**: Identified in acute undifferentiated leukemia (AUL).\n",
            "- **Prevalence in MPAL**: Found in about 20-30% of T/myeloid MPAL.\n",
            "- **BCL11B in Other Leukemias**: Also identified in AML with minimal differentiation or without maturation and approximately 20-30% of early T-cell precursor ALL (ETP-ALL), suggesting a biological continuum.\n",
            "------------------------------------------------------------\n",
            "Chunk #51, Size: 199\n",
            "Content: These findings demonstrate the intricate nature of ALAL and MPAL, underlining the importance of precise diagnosis and understanding their molecular characteristics for effective treatment strategies.\n",
            "------------------------------------------------------------\n",
            "Chunk #52, Size: 775\n",
            "Content: #### 20225th WHO classification (WHO-HAEM5): Acute leukemias of ambiguous lineage (ALAL)\n",
            "- Acute leukemia of ambiguous lineage with defining genetic abnormalities\n",
            "- Mixed-phenotype acute leukemia with BCR::ABL1 fusion\n",
            "- Mixed-phenotype acute leukemia with KMT2A rearrangement\n",
            "- Acute leukemia of ambiguous lineage with other defined genetic alterations\n",
            "\t- Mixed-phenotype acute leukemia with ZNF384 rearrangement\n",
            "\t- Acute leukemia of ambiguous lineage with BCL11B rearrangement\n",
            "- Acute leukemia of ambiguous lineage, immunophenotypically defined\n",
            "- Mixed-phenotype acute leukemia, B/myeloid\n",
            "- Mixed-phenotype acute leukemia, T/myeloid\n",
            "- Mixed-phenotype acute leukemia, rare types\n",
            "- Acute leukemia of ambiguous lineage, not otherwise specified\n",
            "- Acute undifferentiated leukemia\n",
            "------------------------------------------------------------\n",
            "Chunk #53, Size: 485\n",
            "Content: >[!note] #### 2023 International Consensusu Classification (ICC): Acute leukemias of ambiguous lineage (ALAL)\n",
            ">- Acute leukemia of ambiguous lineage\n",
            ">- Acute undifferentiated leukemia\n",
            ">- Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR::ABL1\n",
            ">- MPAL, with t(v;11q23.3); KMT2A rearranged\n",
            ">- MPAL, B/myeloid, NOS\n",
            ">- MPAL, T/myeloid, NOS\n",
            "\n",
            "### 2024 5th WHO classification (WHO-HAEM5): Lineage Assignment Criteria for Mixed-Phenotype Acute Leukemia (IHC, flow cytometry)\n",
            "------------------------------------------------------------\n",
            "Chunk #54, Size: 780\n",
            "Content: #### B Lineage\n",
            "- [**Strong CD19 Expression**]:\n",
            "  - Either CD19 is strongly expressed; CD19 intensity in part exceeds 50% of normal B cell progenitor level by flow cytometry\n",
            "  - Or, at least one of the following is also strongly expressed: CD10, CD22, or CD79a.\n",
            "- [**Weak CD19 Expression**]: CD19 intensity does not exceed 50% of normal B progenitor by flow cytometry\n",
            "  - **Multiple Strong Expressions**:\n",
            "  - Two or more of the following are strongly expressed: CD10, CD22, or CD79a.\n",
            "#### T Lineage\n",
            "- **CD3 Expression (Cytoplasmic or Surface)**:\n",
            "  - Intensity in part exceeds 50% of mature T-cells level by flow cytometry or immunocytochemistry positive with non-zeta chain reagent.\n",
            "  - Use of anti-CD3 epsilon chain antibody.\n",
            "#### Myeloid Lineage\n",
            "- **Myeloperoxidase Expression**:\n",
            "------------------------------------------------------------\n",
            "Chunk #55, Size: 568\n",
            "Content: #### T Lineage\n",
            "- **CD3 Expression (Cytoplasmic or Surface)**:\n",
            "  - Intensity in part exceeds 50% of mature T-cells level by flow cytometry or immunocytochemistry positive with non-zeta chain reagent.\n",
            "  - Use of anti-CD3 epsilon chain antibody.\n",
            "#### Myeloid Lineage\n",
            "- **Myeloperoxidase Expression**:\n",
            "  - Either myeloperoxidase is present.\n",
            "\t  - **Intensity Comparison**: Intensity exceeds 50% of mature neutrophil level.\n",
            "  - Or, evidence of monocytic differentiation.\n",
            "\t  - Two or more of the following are expressed: Non-specific esterase, CD11c, CD14, CD64, or lysozyme.\n",
            "------------------------------------------------------------\n",
            "Chunk #56, Size: 109\n",
            "Content: ### 2022 5th WHO classification (WHO-HAEM5): Genetic Tumor Syndromes with Predisposition to Myeloid Neoplasia\n",
            "------------------------------------------------------------\n",
            "Chunk #57, Size: 794\n",
            "Content: #### Fanconi Anemia\n",
            "- **Cause**: Germline variants in the BRCA-Fanconi DNA repair pathway (involving ≥21 genes).\n",
            "- **Effects**: Results in chromosomal breakage and hypersensitivity to crosslinking agents used for diagnosis.\n",
            "- **Clinical Features**: Congenital anomalies, bone marrow failure, and cancer predisposition.\n",
            "- **Hematologic Categories (5 Types)**: Classified based on blast percentage, cytopenia, and chromosomal abnormalities.\n",
            "  - **Key Indicators of Progression**: Dysgranulopoiesis and dysmegakaryopoiesis in histology.\n",
            "#### RASopathies\n",
            "- **Description**: A diverse group of complex, multi-system disorders.\n",
            "- **Genetic Basis**: Variants in genes associated with the RAS mitogen-activating protein kinase (MAPK) pathway.\n",
            "- **Genes for Analysis**: NF1, NRAS, KRAS, PTPN11, and CBL.\n",
            "------------------------------------------------------------\n",
            "Chunk #58, Size: 439\n",
            "Content: #### RASopathies\n",
            "- **Description**: A diverse group of complex, multi-system disorders.\n",
            "- **Genetic Basis**: Variants in genes associated with the RAS mitogen-activating protein kinase (MAPK) pathway.\n",
            "- **Genes for Analysis**: NF1, NRAS, KRAS, PTPN11, and CBL.\n",
            "- **Importance in Diagnosis**: Genomic analysis of these genes is crucial for diagnosing myeloid neoplasms, especially juvenile myelomonocytic leukemia (JMML) in suspected cases.\n",
            "------------------------------------------------------------\n"
          ]
        }
      ]
    }
  ]
}